Document:

Exhibit 10.1

 

AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT

 

THIS
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of January 15, 2020, by and among Interpace Biosciences, Inc., a Delaware corporation (the “Company”), 1315 Capital
II, L.P., a Delaware limited partnership (including its successors and assigns, “1315 Capital”) and
Ampersand 2018 Limited Partnership, a Delaware limited partnership (including its successors and assigns, “Ampersand”
and, together with 1315 Capital, the “Investors” and each an “Investor”).

 

WHEREAS,
the Company and the Investors are parties to a Securities Purchase and Exchange Agreement, dated as of January 10, 2020 (the “Securities
Purchase Agreement”), pursuant to which on the date hereof (a) the Company issued, sold and delivered to the Investors,
and the Investors purchased and acquired from the Company, pursuant to the terms and subject to the conditions set forth therein,
an aggregate of 20,000 shares of the Company’s Series B Convertible Preferred Stock, par value $0.01 per share (the “Series
B Shares”) and (b) the Company issued and delivered 27,000 Series B Shares to Ampersand in exchange for Ampersand’s
270 shares of the Company’s Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Shares”),
representing all issued and outstanding Series A Shares, pursuant to the terms and subject to the conditions set forth therein;

 

WHEREAS,
Series B Shares have the designation, powers, preferences and rights, and the qualifications, limitations and restrictions, as
specified in the Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock
(the “Certificate of Designation”), attached as an exhibit to the Securities Purchase Agreement.

 

WHEREAS,
the Series B Shares are convertible into shares of the Company’s common stock, par value $0.01 per share (“Common
Shares”) pursuant to the Certificate of Designation; and

 

WHEREAS,
the Company and the Investors desire to amend and restate that certain Investor Rights Agreement, dated as of July 15, 2019, among
the Company and Ampersand in order to establish certain terms and conditions concerning the rights of and restrictions on the
Investors with respect to the ownership of the Series B Shares and other capital stock of the Company, and it is a condition of
the closing of the transactions contemplated by the Securities Purchase Agreement that the Company and the Investors execute and
deliver this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.
DEFINITIONS. The following capitalized terms used herein have the following meanings:

 

“1315
Capital Confidentiality Agreement” means that certain Non-Disclosure Agreement, dated as of November 22, 2019, between
the Company and 1315 Capital LLC.

 

“Addendum
Agreement” is defined in Section 9.2.

 

    	1

    	 

    

 

“Affiliate”
means, with respect to any specified Person, any other Person directly or indirectly controlling or controlled by, or under direct
or indirect common control with, such specified Person; provided that the following Persons shall not be deemed to be Affiliates
of any of the Investors or any of their respective Affiliates: (a) the Company and its subsidiaries and (b) any portfolio company
in which any of the Investors or any of their respective Affiliates has an investment (whether debt or equity) or any of such
portfolio companies’ controlled Affiliates, so long as, in the case of this clause (b), such Person shall not have been
acting on behalf of or at the direction of any of the Investors or any of their respective Affiliates or received any Confidential
Information from or on behalf of any of the Investors; provided, however, clause (b) shall not apply to the use of the word “Affiliate”
in the definition of Investor Parties. For the purposes of this definition, “control”, when used with
respect to any specified Person, means the power to direct the management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling”
and “controlled” have meanings correlative to the foregoing.

 

“Ampersand
Confidentiality Agreement” means that certain Letter Agreement, dated as of February 15, 2019, between the Company
and Ampersand Management, LLC.

 

“as
converted basis” means with respect to the outstanding Common Shares as of any date, all outstanding Common Shares
calculated on a basis in which all Common Shares issuable upon conversion of the outstanding Series B Shares (at the “Series
B Conversion Price” in effect on such date as set forth in the Certificate of Designation), are assumed to be outstanding
as of such date.

 

Any
Person shall be deemed to “beneficially own”, to have “beneficial ownership”
of, or to be “beneficially owning” any securities (which securities shall also be deemed “beneficially
owned” by such Person) that such Person is deemed to “beneficially own” within the meaning of Rules
13d-3 and 13d-5 under the Exchange Act; provided that any Person shall be deemed to beneficially own any securities that
such Person has the right to acquire, whether or not such right is exercisable immediately, within 60 days or otherwise (including
assuming conversion of all Series B Shares owned by such Person to Common Shares).

 

“Business
Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Capital
Stock” means, with respect to any Person, any and all shares, interests, participations or other equivalents (however
designated, whether voting or non-voting) of capital stock, partnership interests (whether general or limited) or equivalent ownership
interests in or issued by such Person, and with respect to the Company includes, without limitation, any and all Common Shares
and Series B Shares.

 

“Closing
Date” means the date of this Agreement.

 

“Code”
means the United States Internal Revenue Code of 1986, as amended.

 

“Commission”
means the Securities and Exchange Commission, or any other Federal agency then administering the Securities Act or the Exchange
Act.

 

“Common
Shares” is defined in the recitals to this Agreement.

 

“Company”
is defined in the preamble to this Agreement.

 

“Company
Board” means the Board of Directors of the Company.

 

“Demand
Registration” is defined in Section 2.1.1.

 

“Demand
Takedown” is defined in Section 2.3.4.(a).

 

    	2

    	 

    

 

“Demanding
Holder” is defined in Section 2.1.1.

 

“Effectiveness
Period” is defined in Section 3.1.3.

 

“Equity
Securities” means, with respect to any Person, (x) any shares of Capital Stock of such Person, (y) any rights, options,
warrants or similar securities to subscribe for, purchase or otherwise acquire any shares of Capital Stock of such Person, and
(z) Capital Stock or other equity securities directly or indirectly convertible into or exercisable or exchangeable for any shares
of Capital Stock of such Person, excluding, for all purposes, any debt, including, without limitation, any debt convertible into
any of the foregoing described in clauses (x) through (z).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time.

 

“Exempted
Securities” means (a) Common Shares, options or convertible securities issued as a dividend or distribution on Series
B Shares; (b) Common Shares, options or convertible securities issued by reason of a dividend, stock split, split-up or other
distribution on Common Shares; (c) Common Shares or options issued to employees or directors of, or consultants or advisors to,
the Company or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Company Board, including the
approval of at least one Investor Director; (d) Common Shares or convertible securities actually issued upon the exercise of options
or Common Shares actually issued upon the conversion or exchange of convertible securities, in each case, provided such issuance
is pursuant to the terms of an option or convertible security that is issued and outstanding prior to the Closing Date.

 

“GAAP”
means United States generally accepted accounting principles, as in effect from time to time, consistently applied.

 

“Governmental
Authority” any United States or non-United States (i) federal, national, regional, state, provincial, local, municipal
or other government, (ii) governmental or quasi-governmental entity of any nature (including any governmental agency, branch,
department, official, or entity, any self-regulatory authority, public utility and any supra-national organization, state, county,
city or other political subdivision and any court or other tribunal) or (iii) body exercising or entitled to exercise any administrative,
executive, judicial, legislative, police, regulatory or taxing authority or power of any nature, including any public arbitral
tribunal, arbitrator or mediator.

 

“Indemnified
Party” is defined in Section 4.3.

 

“Indemnifying
Party” is defined in Section 4.3.

 

“Independent
Director” is defined in Section 6.1.1.

 

“Investor”
and “Investors” are defined in the preamble to this Agreement.

 

“Investor
Directors” is defined in Section 6.1.1.

 

“Investor
Indemnified Party” is defined in Section 4.1.

 

“Investor
Parties” means, as applicable, each of the Investors and any of their respective Affiliates, including Affiliates
to whom Series B Shares or Common Shares are transferred pursuant to and in accordance with this Agreement.

 

    	3

    	 

    

 

“Law”
means all applicable constitutions, treaties, statutes, laws (including common law), orders, ordinances, regulations, codes, rules,
legally binding regulatory policy statements, binding standards or guidance, or general binding directives or decrees enacted,
adopted or applied by any and all Governmental Authorities.

 

“Lock-Up
Parties” is defined in Section 2.4.4.

 

“Lock-Up
Period” means the period commencing on the Closing Date and ending one hundred and eighty (180) days following the
Closing Date.

 

“Marketed
Takedown” shall mean a Underwritten Takedown that is a fully marketed underwritten offering that requires Company
management to participate in “road show” presentations to potential investors requiring substantial marketing effort
from management over multiple days.

 

“Maximum
Number of Shares” is defined in Section 2.1.4.

 

“Notices”
is defined in Section 9.3.

 

“Observer”
is defined in Section 6.2.

 

“Participation
Portion” means a fraction the numerator of which is the aggregate number of Common Shares issuable upon the conversion
of the Series B Shares held by an Investor as of the date of the Pre-Emptive Right Notice, and the denominator of which is the
aggregate number of Common Shares issued and outstanding as of the date of the Pre-Emptive Right Notice, assuming for such purposes
that all Series B Shares have been converted into Common Shares in accordance with their terms as of such date.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically
listed herein.

 

“Piggy-Back
Registration” is defined in Section 2.2.1.

 

“Pre-Emptive
Right Notice” is defined in Section 7.1.1.

 

“Registrable
Securities” means (i) any Series B Shares, (ii) any Common Shares issued upon the conversion of the Series B Shares
and (iii) any other Common Shares hereafter acquired by the Investors (and any other securities issued or issuable to the Investors
with respect to the securities referred to in clauses (i), (ii) and (iii) by way of any share split, share dividend or other distribution,
recapitalization, share exchange, share reconstruction, amalgamation, contractual control arrangement or similar event). As to
any particular Registrable Securities, such securities shall cease to be Registrable Securities when: (a) a Registration Statement
with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have
been sold, transferred or disposed of pursuant to such Registration Statement; (b) upon an Investor’s request in writing,
(i) such securities shall have been otherwise transferred pursuant to such written request, (ii) new certificates for them or
registered in such alternative form, in each case not bearing a legend restricting further transfer, shall have been delivered
by the Company in accordance with such written request and (iii) subsequent public distribution of them shall not require registration
under the Securities Act and is permitted under Rule 144A without any volume, manner-of-sale or other conditions; or (c) such
securities shall have ceased to be outstanding. The parties hereto acknowledge that the inclusion of “any Series B Shares”
in the definition of “Registrable Securities” is intended solely to facilitate any registration of Common Shares and
that, in the event the Investors have no rights under this Agreement to effect any public offering of Series B Shares.

 

    	4

    	 

    

 

“Registration”
means a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements
of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such registration statement becoming
effective.

 

“Registration
Statement” means a registration statement filed by the Company with the Commission in compliance with the Securities
Act and the rules and regulations promulgated thereunder for a public offering and sale of equity securities, or securities or
other obligations exercisable or exchangeable for, or convertible into, equity securities (other than a registration statement
on Form S-4 or Form S-8 or their successors, or any registration statement covering only securities proposed to be issued in exchange
for securities or assets of another entity).

 

“Requesting
Holder” is defined in Section 2.3.4(a).

 

“Resale
Shelf Registration Statement” is defined in Section 2.3.1.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder,
all as the same shall be in effect at the time.

 

“Securities
Purchase Agreement” is defined in the recitals to this Agreement.

 

“Selling
Holders” is defined in Section 2.3.4(a)(ii).

 

“Short
Sales” include, without limitation, (i) all “short sales” as defined in Rule 200 promulgated under Regulation
SHO, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts,
calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar
arrangements (including on a total return basis), and (ii) sales and other transactions through non-U.S. broker dealers or foreign
regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Shares).

 

“Standstill
Period” means the period commencing on the Closing Date and ending on the first (1st) anniversary of
the Closing Date.

 

“Underwriter”
means a securities dealer who purchases any Registrable Securities as principal in an underwritten offering and not as part of
such dealer’s market-making activities.

 

“Underwritten
Takedown” shall mean an underwritten public offering of Registrable Securities pursuant to the Resale Shelf Registration
Statement, as amended or supplemented.

 

2.
REGISTRATION RIGHTS.

 

2.1
Demand Registration.

 

2.1.1
Request for Registration. Subject to Section 2.4, at any time and from time to time beginning one year following
the Closing Date, any Investor or a group of Investors may make a written demand to require the Company to effect the Registration
under the Securities Act of all or any portion of their Registrable Securities, as applicable, on Form S-1 or any similar long-form
Registration or, if then available, on Form S-3; provided that the Registrable Securities included in such demand have
an estimated aggregate market value of not less than $5,000,000. Each registration requested pursuant to this Section 2.1.1
is referred to herein as a “Demand Registration”. Any demand for a Demand Registration shall specify
the number of shares of Registrable Securities proposed to be sold and the intended method(s) of distribution thereof. The Company
will notify all Investors that are holders of Registrable Securities of the demand, and each such holder of Registrable Securities
who wishes to include all or a portion of such holder’s Registrable Securities in the Demand Registration (each such holder
including shares of Registrable Securities in such registration, a “Demanding Holder”) shall so notify
the Company within fifteen (15) days after the receipt by the holder of the notice from the Company. Upon any such request, the
Demanding Holders shall be entitled to have their Registrable Securities included in the Demand Registration, subject to Sections
2.1.4 and 3.4 and the provisos set forth in Section 3.1.1.

 

    	5

    	 

    

 

2.1.2
Effective Registration. A Registration will not count as a Demand Registration until the Registration Statement filed with
the Commission with respect to such Demand Registration has been declared effective and the Company has complied with all of its
obligations under this Agreement with respect thereto (including the Company’s maintaining effectiveness for the duration
of the Effectiveness Period (as defined below)); provided, however, that if, after such Registration Statement has
been declared effective, the offering of Registrable Securities pursuant to a Demand Registration is interfered with by any stop
order or injunction of the Commission or any other Governmental Authority or court, the Registration Statement with respect to
such Demand Registration will be deemed not to have been declared effective, unless and until, (i) such stop order or injunction
is removed, rescinded or otherwise terminated, and (ii) the Demanding Holders holding seventy-five percent (75%) of the Registrable
Securities covered by such Registration Statement thereafter elect to continue the offering; provided, further,
that the Company shall not be obligated to file a second Registration Statement until a Registration Statement that has been filed
is counted as a Demand Registration or is terminated.

 

2.1.3
Underwritten Offering. If the Demanding Holders so elect and such holders so advise the Company as part of their written
demand for a Demand Registration, the offering of such Registrable Securities pursuant to such Demand Registration shall be in
the form of an underwritten offering. In such event, the right of any holder to include its Registrable Securities in such Registration
shall be conditioned upon such holder’s participation in such underwriting and the inclusion of such holder’s Registrable
Securities in the underwriting to the extent provided herein. All Demanding Holders proposing to distribute their Registrable
Securities through such underwriting and the Company shall enter into an underwriting agreement in customary form with the Underwriter
or Underwriters selected for such underwriting by the holders initiating the Demand Registration.

 

2.1.4
Reduction of Offering. If the managing Underwriter or Underwriters for a Demand Registration that is to be an underwritten
offering advises the Company and the Demanding Holders in writing that the dollar amount or number of shares of Registrable Securities
which the Demanding Holders desire to sell, taken together with all other Common Shares which the Company desires to sell and
the Common Shares, if any, as to which registration has been requested pursuant to valid written contractual piggy-back registration
rights held by other stockholders of the Company who desire to sell, exceeds the maximum dollar amount or maximum number of shares
that can be sold in such offering without adversely affecting the proposed offering price, the timing, the distribution method,
or the probability of success of such offering (such maximum dollar amount or maximum number of shares, as applicable, the “Maximum
Number of Shares”), then the Company shall include in such registration: (i) first, the Registrable Securities as
to which Demand Registration has been requested by the Demanding Holders (pro rata in accordance with the number of shares held
by each such Person) that can be sold without exceeding the Maximum Number of Shares; (ii) second, to the extent that the Maximum
Number of Shares has not been reached under the foregoing clause (i), the Common Shares that the Company desires to sell that
can be sold without exceeding the Maximum Number of Shares; (iii) third, to the extent that the Maximum Number of Shares has not
been reached under the foregoing clauses (i) and (ii), the Common Shares for the account of other persons that the Company is
obligated to register pursuant to valid written contractual arrangements with such persons, as to which “piggy-back”
registration has been requested by the holders thereof (pro rata in accordance with the number of shares held by each such person)
that can be sold without exceeding the Maximum Number of Shares.

 

    	6

    	 

    

 

2.1.5
Withdrawal. The Demanding Holders holding seventy-five percent (75%) of the Registrable Securities covered by such Registration
Statement shall have the right to require the Company to abandon or withdraw such Registration Statement by giving written notice
to the Company and the managing Underwriter or Underwriters of such request prior to the effectiveness of the Registration Statement
filed with the Commission with respect to such Demand Registration. In such case, the abandoned or withdrawn registration shall
not count for purposes of the number of Demand Registrations permitted pursuant to Section 2.4.1 if (i) more than 20% of
the Registrable Securities requested by such Demanding Holders to be included in such registration are not or would not have been
so included or (ii) a material adverse change in the Company’s business, operations, financial condition, operating results
or prospects or the price to the public at which the Registrable Securities are proposed to be sold in such registration has occurred;
provided that if such Demanding Holders require the Company to abandon or withdraw such Registration Statement for any
other reason, the abandoned or withdrawn registration shall also not count for purposes of the number of Demand Registrations
permitted pursuant to Section 2.4.1 if such Demanding Holders reimburse the Company for the Demanding Holders’ costs
associated with the abandoned or withdrawn registration.

 

2.2
Piggy-Back Registration.

 

2.2.1
Piggy-Back Rights. If at any time from time to time, the Company proposes to file a Registration Statement under the Securities
Act with respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible
into, equity securities, by the Company for its own account or for stockholders of the Company for their account (or by the Company
and by stockholders of the Company including, without limitation, pursuant to Section 2.3), other than a Registration Statement
(i) filed in connection with any employee stock option or other benefit plan, (ii) for an exchange offer or offering of securities
solely to the Company’s existing stockholders, (iii) for an offering of debt that is convertible into equity securities
of the Company or (iv) for a dividend reinvestment plan, then the Company shall (x) give written notice of such proposed filing
to the holders of Registrable Securities as soon as practicable but in no event less than ten (10) days before the anticipated
filing date, which notice shall describe the amount and type of securities to be included in such offering, the intended method(s)
of distribution, and the name of the proposed managing Underwriter or Underwriters, if any, of the offering, and (y) offer to
the holders of Registrable Securities in such notice the opportunity to register the sale of such number of shares of Registrable
Securities as such holders may request in writing within five (5) days following receipt of such notice (a “Piggy-Back
Registration”). Subject to receipt of the information from the holders of Registrable Securities set forth in Section
3.4, the Company shall cause such Registrable Securities to be included in such registration and shall use its best efforts
to cause the managing Underwriter or Underwriters of a proposed underwritten offering to permit the Registrable Securities requested
to be included in a Piggy-Back Registration on the same terms and conditions as any similar securities of the Company and to permit
the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof.
The Company and all holders of Registrable Securities proposing to distribute their securities through a Piggy-Back Registration
that involves an Underwriter or Underwriters shall enter into an underwriting agreement in customary form with the Underwriter
or Underwriters selected for such Piggy-Back Registration.

 

    	7

    	 

    

 

2.2.2
Reduction of Offering. If the managing Underwriter or Underwriters for a Piggy-Back Registration that is to be an underwritten
offering advises the Company and the holders of Registrable Securities in writing that the dollar amount or number of Common Shares
which the Company desires to sell, taken together with Common Shares, if any, as to which registration has been demanded pursuant
to valid written contractual arrangements with persons other than the holders of Registrable Securities hereunder and the Registrable
Securities as to which registration has been requested under this Section 2.2, exceeds the Maximum Number of Shares, then
the Company shall include in any such registration:

 

(a)
If the registration is undertaken for the Company’s account: (A) first, the Common Shares or other securities that the Company
desires to sell that can be sold without exceeding the Maximum Number of Shares; and (B) second, to the extent that the Maximum
Number of Shares has not been reached under the foregoing clause (A), the Common Shares or other securities, if any, comprised
of Registrable Securities, as to which registration has been requested pursuant to the terms hereof, that can be sold without
exceeding the Maximum Number of Shares, pro rata based on the total number of Registrable Securities held by the Investors; and
(C) third, to the extent that the Maximum Number of shares has not been reached under the foregoing clauses (A) and (B), the Common
Shares or other securities for the account of other persons that the Company is obligated to register pursuant to valid written
contractual piggy-back registration rights with such persons and that can be sold without exceeding the Maximum Number of Shares;
and

 

(b)
If the registration is a “demand” registration undertaken at the demand of persons other than the holders of Registrable
Securities, (A) first, the Common Shares or other securities for the account of the demanding persons and the holders of Registrable
Securities exercising their piggy-back registration rights pursuant to the terms hereof, pro rata based on the total number of
fully diluted Common Shares held by such selling holders, that can be sold without exceeding the Maximum Number of Shares; (B)
second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (A), the Common Shares
or other securities that the Company desires to sell that can be sold without exceeding the Maximum Number of Shares; and (C)
third, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A) and (B), the Common
Shares or other securities for the account of other persons that the Company is obligated to register pursuant to valid written
contractual arrangements with such persons, that can be sold without exceeding the Maximum Number of Shares.

 

2.2.3
Withdrawal. Any holder of Registrable Securities may elect to withdraw such holder’s request for inclusion of Registrable
Securities in any Piggy-Back Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness
of the Registration Statement. With respect to registrations not initiated by holders of Registrable Securities and to which such
holders are participating solely through their piggy-back registration rights, the Company (whether on its own determination or
as the result of a withdrawal by persons making a demand pursuant to valid written contractual obligations) may withdraw a Registration
Statement at any time prior to the effectiveness of such Registration Statement. Notwithstanding any such withdrawal, the Company
shall pay all expenses incurred by the holders of Registrable Securities in connection with such Piggy-Back Registration as provided
in Section 3.3.

 

2.3
Resale Shelf Registration Rights.

 

2.3.1
Registration Statement Covering Resale of Registrable Securities. On or prior to the first anniversary of the Closing Date,
upon the written demand of an Investor or group of Investors and subject to receipt of the information from the holders of Registrable
Securities set forth in Section 3.4, the Company shall promptly effect an effective Registration Statement permitting offerings
to be made on a continuous basis pursuant to Rule 415 under the Securities Act registering the resale from time to time by Investors
of all of the Registrable Securities held by or then-issuable to the Investors (the “Resale Shelf Registration Statement”).
The Company will notify all Investors that are holders of Registrable Securities of the demand and that they will include in the
Resale Shelf Registration Statement such Investor’s Registrable Securities. The Resale Shelf Registration Statement shall
be on Form S-3 or another appropriate form permitting Registration of such Registrable Securities for resale by such Investors.
If, on the date that the Resale Shelf Registration Statement is filed, the Company is a well-known seasoned issuer (as defined
in Rule 405 under the Securities Act) (a “WKSI”), then the Company shall file the Resale Shelf Registration
Statement as an automatic shelf registration statement (as defined in Rule 405 under the Securities Act), which shall be effective
upon the filing thereof. If the Company is not a WKSI on the date of the written demand, the Company shall make the initial filing
of the Resale Shelf Registration Statement within forty-five (45) days of receipt of the written demand. Once the Resale Shelf
Registration Statement is effective, the Company shall use commercially reasonable efforts to keep the Resale Shelf Registration
Statement continuously effective under the Securities Act at all times until the expiration of the Effectiveness Period. If any
Registrable Securities are outstanding at the expiration of the Effectiveness Period, the Company is obligated to file and make
effective a subsequent Resale Shelf Registration Statement on or prior to the expiration of the Effectiveness Period in accordance
with this Section 2.3.1 registering the resale from time to time by Investors of all of the Registrable Securities held
by or then issuable to the Investors.

 

    	8

    	 

    

 

2.3.2
Notification and Distribution of Materials. The Company shall notify the Investors in writing of the effectiveness of the
Resale Shelf Registration Statement and shall furnish to them, without charge, such number of copies of the Resale Shelf Registration
Statement (including any amendments, supplements and exhibits), the prospectus contained therein (including each preliminary prospectus
and all related amendments and supplements) and any documents incorporated by reference in the Resale Shelf Registration Statement
or such other documents as the Investors may reasonably request in order to facilitate the sale of the Registrable Securities
in the manner described in the Resale Shelf Registration Statement.

 

2.3.3
Amendments and Supplements. Subject to the provisions of Section 2.3.1 above, the Company shall promptly prepare
and file with the Commission from time to time such amendments and supplements to the Resale Shelf Registration Statement and
prospectus used in connection therewith as may be necessary to keep the Resale Shelf Registration Statement effective and to comply
with the provisions of the Securities Act with respect to the disposition of all the Registrable Securities during the Effectiveness
Period.

 

2.3.4
Notice of Certain Events. The Company shall promptly notify the Investors in writing of any request by the Commission for
any amendment or supplement to, or additional information in connection with, the Resale Shelf Registration Statement required
to be prepared and filed hereunder (or prospectus relating thereto). The Company shall promptly notify each Investor in writing
of the filing of the Resale Shelf Registration Statement or any prospectus, amendment or supplement related thereto or any post-effective
amendment to the Resale Shelf Registration Statement and the effectiveness of any post-effective amendment.

 

(a)
If the Company shall receive a request from one or more holders of Registrable Securities (the requesting holder(s) shall be referred
to herein as the “Requesting Holder”), provided that the estimated aggregate market value of the Registrable
Securities is at least $5,000,000 for a Marketed Takedown, that the Company effect an Underwritten Takedown of all or any portion
of the Requesting Holder’s Registrable Securities, and specifying the intended method of disposition thereof (including
whether such Underwritten Takedown is intended to be a Marketed Takedown), then the Company shall promptly give notice of such
requested Underwritten Takedown (each such request shall be referred to herein as a “Demand Takedown”)
at least five (5) Business Days prior to the anticipated filing date of the prospectus or supplement relating to such Demand Takedown
to the other Investors and thereupon shall use its commercially reasonable efforts to effect, as expeditiously as possible, the
offering in such Underwritten Takedown of:

 

(i)
subject to the restrictions set forth in Section 2.1.4, all Registrable Securities for which the Requesting Holder has
requested such offering under Section 2.3.4(a), and

 

(ii)
subject to the restrictions set forth in Section 2.1.4, all other Registrable Securities that any holders of Registrable
Securities (all such holders, together with the Requesting Holder, the “Selling Holders”) have requested
the Company to offer by request received by the Company within two (2) Business Days after such holders receive the Company’s
notice of the Demand Takedown, all to the extent necessary to permit the disposition (in accordance with the intended methods
thereof as aforesaid) of the Registrable Securities so to be offered.

 

    	9

    	 

    

 

(b)
Promptly after the expiration of the two (2) Business Day period referred to in Section 2.3.4(a)(ii), the Company will
notify all Selling Holders of the identities of the other Selling Holders and the number of shares of Registrable Securities requested
to be included therein.

 

(c)
If the managing underwriter in an Underwritten Takedown advises the Company and the Requesting Holder that, in its view, the number
of shares of Registrable Securities requested to be included in such underwritten offering exceeds the largest number of shares
that can be sold without having an adverse effect on such offering, including the price at which such shares can be sold, the
shares included in such Underwritten Takedown will be reduced by the Registrable Securities held by the Selling Holders (on a
pro rata basis based on the total number of Registrable Securities held by such Selling Holders, subject to a determination by
the Commission that certain Selling Holders must be reduced first based on the number of Registrable Securities held by such Selling
Holders).

 

2.3.5
Selection of Underwriters. Selling Holders holding seventy-five percent (75%) of the Registrable Securities requested to
be sold in an Underwritten Takedown shall have the right to select an Underwriter or Underwriters in connection with such Underwritten
Takedown, which Underwriter or Underwriters shall be reasonably acceptable to the Company (which consent shall not be unreasonably
withheld, conditioned or delayed). In connection with an Underwritten Takedown, the Company shall enter into customary agreements
(including an underwriting agreement in customary form) and take such other actions as are reasonably required in order to expedite
or facilitate the disposition of the Registrable Securities in such Underwritten Takedown, including, if necessary, the engagement
of a “qualified independent underwriter” in connection with the qualification of the underwriting arrangements with
the Financial Industry Regulatory Authority, Inc.

 

2.4
Registration Rights Limitations.

 

2.4.1
The Company shall not be obligated to effectuate more than an aggregate of two (2) Demand Registrations.

 

2.4.2
The Company shall not be obligated to effectuate more than (i) two (2) Marketed Takedowns in any 365-day period or (ii) an aggregate
of two (2) Marketed Takedowns.

 

2.4.3
For so long as a Resale Shelf Registration Statement is effective with respect to all Registrable Securities of an Investor and
such Investor is able to sell its Registrable Securities in a takedown offering pursuant to such Resale Shelf Registration Statement,
such Investor’s right to make a Demand Registration of such Registrable Securities pursuant to Section 2.1 is suspended.

 

2.4.4
If any sale of Registrable Securities shall be effected by means of an underwritten offering, (a) each of the Investors, the members
of the Company Board and the executive officers of the Company (collectively, the “Lock-Up Parties”)
shall enter into a customary “lock-up” agreement (which lock-up agreements shall contain identical terms) in favor
of the underwriters and (b) neither the Company nor any Lock-Up Party shall effect any public sale or distribution of any of the
Company’s securities (except as part of such underwritten offering), including any sale pursuant to Rule 144 or by entering
into any swap, hedge or other arrangement that transfers, in whole or in part, the economic consequence of ownership of such securities,
during the ten (10) Business Days prior to, and continuing for ninety (90) Business Days after, the date of the pricing of such
underwritten offering (unless the underwriters, the Company and the Investors agree on a different time period). The foregoing
notwithstanding, no Lock-Up Party shall be required to terminate an existing 10b5-1 plan or to cease sales under any such plan.
No Lock-Up Party holding any class of securities subject to this Section 2.4.4 shall be released from any obligation under
any agreement, arrangement or understanding entered into with respect to this Section 2.4.4 unless the Investors are also
released.

 

    	10

    	 

    

 

2.4.5
The Company shall not, without the prior written consent of the Investors, enter into any agreement with any holder or prospective
holder of any security of the Company giving such holder or prospective holder any registration rights the terms of which are
more favorable than the registration rights granted to the holders of Registrable Securities hereunder, or which would reduce
the amount of Registrable Securities such holders can include in any (i) registration statement filed pursuant to Sections
2.1 and 2.3.1 hereunder or (ii) Underwritten Takedown pursuant to Section 2.3.4 hereunder, unless such rights
are subordinate to those of the holders of Registrable Securities.

 

3.
REGISTRATION PROCEDURES.

 

3.1
Filings; Information. Whenever the Company is required to effect the registration of any Registrable Securities pursuant
to Section 2, the Company shall use its commercially reasonable efforts to effect the registration and sale of such Registrable
Securities in accordance with the intended method(s) of distribution thereof as expeditiously as practicable, and in connection
with any such request:

 

3.1.1
Filing Registration Statement. The Company shall use its commercially reasonable efforts to, as expeditiously as possible
after receipt of a request for a Demand Registration pursuant to Section 2.1, prepare and file with the Commission a Registration
Statement on any form for which the Company then qualifies or which counsel for the Company shall deem appropriate and which form
shall be available for the sale of all Registrable Securities to be registered thereunder in accordance with the intended method(s)
of distribution thereof, and shall use its commercially reasonable efforts to cause such Registration Statement to become effective
and use its commercially reasonable efforts to keep it effective for the Effectiveness Period; provided, however,
that the Company shall have the right to defer any Demand Registration for up to forty-five (45) days, and any Piggy-Back Registration
for such period as may be applicable to deferment of any Demand Registration to which such Piggy-Back Registration relates, in
each case if the Company shall furnish to the holders a certificate signed by the chief executive officer and chief financial
officer of the Company stating that, in the good faith judgment of the Company Board, if the Registration Statement were to be
effected at such time, it would (i) materially interfere with a bona fide material acquisition, corporate organization or other
similar transaction involving the Company or (ii) require premature disclosure of material information that the Company has a
bona fide business purpose for preserving as confidential, the premature disclosure of which would materially adversely affect
the Company; provided, further, however, that the Company shall not have the right to exercise the right
set forth in the immediately preceding proviso for more than a total of ninety (90) days in any 365-day period.

 

3.1.2
Copies. The Company shall, prior to filing a Registration Statement or prospectus, or any amendment or supplement thereto,
furnish without charge to the holders of Registrable Securities included in such registration, and such holders’ legal counsel,
copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in
each case including all exhibits thereto and documents incorporated by reference therein), the prospectus included in such Registration
Statement (including each preliminary prospectus) and such other documents as the holders of Registrable Securities included in
such registration or legal counsel for any such holders may request in order to facilitate the disposition of the Registrable
Securities owned by such holders.

 

    	11

    	 

    

 

3.1.3
Amendments and Supplements. The Company shall prepare and file with the Commission such amendments, including post-effective
amendments, and supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary
to keep such Registration Statement effective and in compliance with the provisions of the Securities Act until the date on which
all Registrable Securities and other securities covered by such Registration Statement have been disposed of in accordance with
the intended method(s) of distribution set forth in such Registration Statement or such securities have been withdrawn (the “Effectiveness
Period”).

 

3.1.4
Notification. After the filing of a Registration Statement, the Company shall promptly, and in no event more than two (2)
Business Days after such filing, notify the holders of Registrable Securities included in such Registration Statement of such
filing, and shall further notify such holders within two (2) Business Days of the occurrence of any of the following: (i) when
such Registration Statement becomes effective; (ii) when any post-effective amendment to such Registration Statement becomes effective;
(iii) the issuance or threatened issuance by the Commission of any stop order (and the Company shall take all actions required
to prevent the entry of such stop order or to remove it if entered); and (iv) any request by the Commission for any amendment
or supplement to such Registration Statement or any prospectus relating thereto or for additional information or of the occurrence
of an event requiring the preparation of a supplement or amendment to such prospectus so that, as thereafter delivered to the
purchasers of the securities covered by such Registration Statement, such prospectus will not contain an untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not
misleading, and promptly make available to the holders of Registrable Securities included in such Registration Statement any such
supplement or amendment; except that before filing with the Commission a Registration Statement or prospectus or any amendment
or supplement thereto, including documents incorporated by reference, the Company shall furnish to the holders of Registrable
Securities included in such Registration Statement and to the legal counsel for any such holders, copies of all such documents
proposed to be filed sufficiently in advance of filing to provide such holders and legal counsel with a reasonable opportunity
to review such documents and comment thereon.

 

3.1.5
Securities Laws Compliance. The Company shall use its commercially reasonable efforts to (i) register or qualify the Registrable
Securities covered by the Registration Statement under such securities or “blue sky” laws of such jurisdictions in
the United States as the holders of Registrable Securities included in such Registration Statement (in light of their intended
plan of distribution) may reasonably request and (ii) take such action necessary to cause such Registrable Securities covered
by the Registration Statement to be registered with or approved by such other governmental authorities as may be necessary by
virtue of the business and operations of the Company and do any and all other acts and things that may be necessary or advisable
to enable the holders of Registrable Securities included in such Registration Statement to consummate the disposition of such
Registrable Securities in such jurisdictions; provided, however, that the Company shall not be required to qualify
generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this paragraph or subject
itself to taxation in any such jurisdiction.

 

3.1.6
Agreements for Disposition. The Company shall enter into customary agreements (including, if applicable, an underwriting
agreement in customary form) and take such other actions as are reasonably required in order to expedite or facilitate the disposition
of such Registrable Securities. The representations, warranties and covenants of the Company in any underwriting agreement which
are made to or for the benefit of any Underwriters, to the extent applicable, shall also be made to and for the benefit of the
holders of Registrable Securities included in such registration statement, and the representations, warranties and covenants of
the holders of Registrable Securities included in such registration statement in any underwriting agreement which are made to
or for the benefit of any Underwriters, to the extent applicable, shall also be made to and for the benefit of the Company.

 

    	12

    	 

    

 

3.1.7
Comfort Letter. The Company shall obtain a “cold comfort” letter from the Company’s independent registered
public accountants in the event of an underwritten offering, in customary form and covering such matters of the type customarily
covered by “cold comfort” letters as the managing Underwriter may reasonably request, and as are reasonably satisfactory
to participating holders holding seventy-five percent (75%) of the Registrable Securities included in such offering.

 

3.1.8
Opinions. On the date the Registrable Securities are delivered for sale pursuant to any Registration or Underwritten Takedown,
the Company shall obtain an opinion, dated such date, of one (1) counsel representing the Company for the purposes of such Registration,
addressed to the holders, the placement agent or sales agent, if any, and the Underwriters, if any, covering such legal matters
with respect to the Registration in respect of which such opinion is being given as the holders, placement agent, sales agent
or Underwriter may reasonably request and as are customarily included in such opinions, and as are reasonably satisfactory to
participating holders holding seventy-five percent (75%) of the Registrable Securities included in such offering.

 

3.1.9
Cooperation. The principal executive officer of the Company, the principal financial officer of the Company, the principal
accounting officer of the Company and all other officers and members of the management of the Company shall cooperate fully in
any offering of Registrable Securities hereunder, which cooperation shall include, without limitation, the preparation of the
Registration Statement with respect to such offering and all other offering materials and related documents, and participation
in meetings with Underwriters, attorneys, accountants and potential investors.

 

3.1.10
Records. Upon execution of confidentiality agreements, the Company shall make available for inspection by the holders of
Registrable Securities included in such Registration Statement, any Underwriter participating in any disposition pursuant to such
registration statement and any attorney, accountant or other professional retained by any holder of Registrable Securities included
in such Registration Statement or any Underwriter, all financial and other records, pertinent corporate documents and properties
of the Company, as shall be necessary to enable them to exercise their due diligence responsibility, and cause the Company’s
officers, directors and employees to supply all information requested by any of them in connection with such Registration Statement.

 

3.1.11
Listing. The Company shall use its commercially reasonable efforts to cause all Registrable Securities included in any
Registration Statement to be listed on such exchanges or otherwise designated for trading in the same manner as similar securities
issued by the Company are then listed or designated.

 

3.2
Obligation to Suspend Distribution. Upon receipt of any written notice from the Company of the happening of any event of
the kind described in Section 3.1.4(iv), or, upon any suspension by the Company, pursuant to a written insider trading
compliance program adopted by the Company Board, of the ability of all “insiders” covered by such program to transact
in the Company’s securities because of the existence of material non-public information, each holder of Registrable Securities
included in any registration shall immediately discontinue disposition of such Registrable Securities pursuant to the Registration
Statement covering such Registrable Securities until such holder receives the supplemented or amended prospectus contemplated
by Section 3.1.4(iv) or the restriction on the ability of “insiders” to transact in the Company’s securities
is removed, as applicable, and, if so directed by the Company, each such holder will deliver to the Company all copies, other
than permanent file copies then in such holder’s possession, of the most recent prospectus covering such Registrable Securities
at the time of receipt of such notice.

 

    	13

    	 

    

 

3.3
Registration Expenses. The Company shall bear all costs and expenses incurred in connection with the Resale Shelf Registration
Statement pursuant to Section 2.3, any Demand Registration pursuant to Section 2.1, any Demand Takedown pursuant
to Section 2.3.4(a), any Piggy-Back Registration pursuant to Section 2.2, any other distribution pursuant to the
terms hereof and all expenses incurred in performing or complying with its other obligations under this Agreement, whether or
not the Registration Statement becomes effective, including, without limitation: (i) all registration and filing fees; (ii) fees
and expenses of compliance with securities or “blue sky” laws (including fees and disbursements of counsel in connection
with blue sky qualifications of the Registrable Securities); (iii) printing expenses; (iv) the Company’s internal expenses
(including, without limitation, all salaries and expenses of its officers and employees); (v) the fees and expenses incurred in
connection with the listing of the Registrable Securities as required by Section 3.1.11; (vi) Financial Industry Regulatory
Authority fees; (vii) fees and disbursements of counsel for the Company and fees and expenses for independent certified public
accountants retained by the Company; (viii) the fees and expenses of any special experts retained by the Company in connection
with such registration and (ix) the reasonable fees and expenses of one (1) legal counsel selected by participating holders holding
seventy-five percent (75%) of the Registrable Securities included in such Registration or offering. The Company shall have no
obligation to pay any underwriting discounts or selling commissions attributable to the Registrable Securities being sold by the
holders thereof, which underwriting discounts or selling commissions shall be borne by such holders.

 

3.4
Information. The holders of Registrable Securities shall promptly provide such information as may reasonably be requested
by the Company, or the managing Underwriter, if any, in connection with the preparation of any Registration Statement, including
amendments and supplements thereto, in order to effect the registration of any Registrable Securities under the Securities Act
and in connection with the Company’s obligation to comply with applicable state securities laws, including each participating
holder delivering to the Company a fully completed and duly executed Selling Stockholder Questionnaire, a form of which is attached
hereto as Exhibit B.

 

4.
INDEMNIFICATION AND CONTRIBUTION.

 

4.1
Indemnification by the Company. The Company agrees to indemnify and hold harmless each Investor and each other holder of
Registrable Securities, and each of their respective officers, employees, affiliates, directors, partners, members, attorneys
and agents, and each person, if any, who controls an Investor and each other holder of Registrable Securities (within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act) (each, an “Investor Indemnified Party”),
from and against any expenses, losses, judgments, claims, damages or liabilities, whether joint or several, arising out of or
based upon any untrue statement (or allegedly untrue statement) of a material fact contained in any Registration Statement under
which the sale of such Registrable Securities was registered under the Securities Act, any preliminary prospectus, final prospectus
or summary prospectus contained in the Registration Statement, or any amendment or supplement to such Registration Statement,
any “free writing prospectus” (as defined in Rule 405 under the Securities Act), or any “issuer information”
(as defined in Rule 433 under the Securities Act) or any “road show” (as defined in Rule 433 under the Securities
Act), or arising out of or based upon any omission (or alleged omission) to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, or any violation by the Company of the Securities Act or any rule
or regulation promulgated thereunder applicable to the Company and relating to action or inaction required of the Company in connection
with any such registration; and the Company shall promptly reimburse the Investor Indemnified Party for any legal and any other
expenses reasonably incurred by such Investor Indemnified Party in connection with investigating and defending any such expense,
loss, judgment, claim, damage, liability or action; provided, however, that the Company will not be liable in any
such case to the extent that any such expense, loss, claim, damage or liability arises out of or is based upon any untrue statement
or allegedly untrue statement or omission or alleged omission made in such Registration Statement, preliminary prospectus, final
prospectus, or summary prospectus, or any such amendment or supplement, any “free writing prospectus” (as defined
in Rule 405 under the Securities Act), or any “road show” (as defined in Rule 433 under the Securities Act) in reliance
upon and in conformity with information furnished to the Company, in writing, by such selling holder expressly for use therein.

 

    	14

    	 

    

 

4.2
Indemnification by Holders of Registrable Securities. Each selling holder of Registrable Securities will severally, in
the event that any registration is being effected under the Securities Act pursuant to this Agreement of any Registrable Securities
held by such selling holder, indemnify and hold harmless the Company, each of its directors and officers against any losses, claims,
judgments, damages or liabilities, whether joint or several, insofar as such losses, claims, judgments, damages or liabilities
(or actions in respect thereof) arise out of or are based upon any untrue statement or allegedly untrue statement of a material
fact contained in any Registration Statement under which the sale of such Registrable Securities was registered under the Securities
Act, any preliminary prospectus, final prospectus or summary prospectus contained in the Registration Statement, or any amendment
or supplement to the Registration Statement, any “free writing prospectus” (as defined in Rule 405 under the Securities
Act), or any “issuer information” (as defined in Rule 433 under the Securities Act) or any “road show”
(as defined in Rule 433 under the Securities Act), or arise out of or are based upon any omission or the alleged omission to state
a material fact required to be stated therein or necessary to make the statement therein not misleading, if the statement or omission
was made in reliance upon and in conformity with information furnished in writing to the Company by such selling holder expressly
for use therein, and shall reimburse the Company, its directors and officers for any legal or other expenses reasonably incurred
by any of them in connection with investigation or defending any such loss, claim, damage, liability or action. Each selling holder’s
indemnification obligations hereunder shall be several and not joint and shall be limited to the amount of any net proceeds actually
received by such selling holder.

 

4.3
Conduct of Indemnification Proceedings. Promptly after receipt by any person of any notice of any loss, claim, damage or
liability or any action in respect of which indemnity may be sought pursuant to Sections 4.1 or 4.2, such person
(the “Indemnified Party”) shall, if a claim in respect thereof is to be made against any other person
for indemnification hereunder, notify such other person (the “Indemnifying Party”) in writing of the
loss, claim, judgment, damage, liability or action; provided, however, that the failure by the Indemnified Party
to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability which the Indemnifying Party may
have to such Indemnified Party hereunder, except and solely to the extent the Indemnifying Party is actually prejudiced by such
failure. If the Indemnified Party is seeking indemnification with respect to any claim or action brought against the Indemnified
Party, then the Indemnifying Party shall be entitled to participate in such claim or action, and, to the extent that it wishes,
jointly with all other Indemnifying Parties, to assume control of the defense thereof with counsel satisfactory to the Indemnified
Party. After notice from the Indemnifying Party to the Indemnified Party of its election to assume control of the defense of such
claim or action, the Indemnifying Party shall not be liable to the Indemnified Party for any legal or other expenses subsequently
incurred by the Indemnified Party in connection with the defense thereof other than reasonable costs of investigation; provided,
however, that in any action in which both the Indemnified Party and the Indemnifying Party are named as defendants, the Indemnified
Party shall have the right to employ separate counsel (but no more than one (1) such separate counsel, which counsel is reasonably
acceptable to the Indemnifying Party) to represent the Indemnified Party and its controlling persons who may be subject to liability
arising out of any claim in respect of which indemnity may be sought by the Indemnified Party against the Indemnifying Party,
with the fees and expenses of such counsel to be paid by such Indemnifying Party if, based upon the written opinion of counsel
of such Indemnified Party, representation of both parties by the same counsel would be inappropriate due to actual or potential
differing interests between them. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, consent
to entry of judgment or effect any settlement of any claim or pending or threatened proceeding in respect of which the Indemnified
Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such judgment
or settlement includes an unconditional release of such Indemnified Party from all liability arising out of such claim or proceeding.

 

    	15

    	 

    

 

4.4
Contribution.

 

4.4.1
If the indemnification provided for in the foregoing Sections 4.1, 4.2 and 4.3 is unavailable to any Indemnified
Party in respect of any loss, claim, damage, liability or action referred to herein, then each such Indemnifying Party, in lieu
of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of
such loss, claim, damage, liability or action in such proportion as is appropriate to reflect the relative fault of the Indemnified
Parties and the Indemnifying Parties in connection with the actions or omissions which resulted in such loss, claim, damage, liability
or action, as well as any other relevant equitable considerations. The relative fault of any Indemnified Party and any Indemnifying
Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by such Indemnified Party or such
Indemnifying Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission.

 

4.4.2
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 4.4.2 were determined
by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred
to in the immediately preceding Section 4.4.1.

 

4.4.3
The amount paid or payable by an Indemnified Party as a result of any loss, claim, damage, liability or action referred to in
the immediately preceding paragraphs shall be deemed to include, subject to the limitations set forth above, any legal or other
expenses incurred by such Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding
the provisions of this Section 4.4, no holder of Registrable Securities shall be required to contribute any amount in excess
of the dollar amount of the net proceeds (after payment of any underwriting fees, discounts, commissions or taxes) actually received
by such holder from the sale of Registrable Securities which gave rise to such contribution obligation. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation.

 

5.
UNDERWRITING AND DISTRIBUTION.

 

5.1
Rule 144. The Company covenants that it shall file any reports required to be filed by it under the Securities Act and
the Exchange Act and shall take such further action as the holders of Registrable Securities may reasonably request, all to the
extent required from time to time to enable such holders to sell Registrable Securities without registration under the Securities
Act within the limitation of the exemptions provided by Rule 144 under the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission.

 

6.
BOARD OF DIRECTORS MATTERS.

 

6.1
Directors.

 

6.1.1
The Company Board will take the actions necessary such that, effective as of the Closing Date, the Company Board shall be comprised
of:

 

(a)
two (2) Class I Directors, (i) one of whom shall qualify as an “independent director” under Rule 5605(a)(2) of the
of the listing rules of the Nasdaq Stock Market (or any successor rule) or under any similar rule promulgated by such other exchange
on which the Company’s securities are then listed or designated (such director, an “Independent Director”),
and shall initially be Stephen J. Sullivan and (ii) one of whom shall be designated by Ampersand and shall initially be Eric Lev;

 

    	16

    	 

    

 

(b)
three (3) Class II Directors, (i) one of whom shall be an Independent Director designated by Ampersand and shall initially be
Robert Gorman, (ii) one of whom shall be an Independent Director designated by 1315 at a future date, and (iii) one of whom shall
be designated by 1315 and shall initially be Edward Chan; and

 

(c)
two (2) Class III Directors, (i) one of whom shall initially be Jack Stover, and (ii) one of whom shall be an Independent Director
and shall initially be Dr. Joseph Keegan.

 

6.1.2
For so long as Ampersand holds at least sixty percent (60%) of the Series B Shares held by Ampersand as of the Closing Date, Ampersand
shall be entitled to elect two (2) directors of the Company, provided that one (1) director elected by Ampersand must qualify
as an Independent Director. For so long as Ampersand holds less than sixty percent (60%) of the Series B Shares held by Ampersand
as of the Closing Date but at least forty percent (40%) of the Series B Shares held by Ampersand as of the Closing Date, Ampersand
shall be entitled to elect one (1) director of the Company. Each director elected pursuant to this Section 6.1.2 is referred
to herein as an “Ampersand Director.”

 

6.1.3
For so long as 1315 Capital holds at least sixty percent (60%) of the Series B Shares held by 1315 Capital as of the Closing Date,
1315 Capital shall be entitled to elect two (2) directors of the Company, provided that one (1) director elected by 1315 Capital
must qualify as an Independent Director. For so long as 1315 Capital holds less than sixty percent (60%) of the Series B Shares
held by 1315 Capital as of the Closing Date but at least forty percent (40%) of the Series B Shares held by 1315 Capital as of
the Closing Date, 1315 Capital shall be entitled to elect one (1) director of the Company. Each director elected pursuant to this
Section 6.1.3 is referred to herein as a “1315 Capital Director” and, together with the Ampersand
Director, the “Investor Directors.”

 

6.1.4
From and after the Closing Date, subject to the rules and regulations regarding director independence of the Nasdaq Stock Market
or such other exchange on which the Company’s securities are then listed or designated, one (1) Ampersand Director and one
(1) 1315 Capital Director shall have the right to serve on each and every committee of the Company Board.

 

6.2
Observation Rights. From and after the Closing Date, 1315 Capital shall have the right to designate one (1) representative,
who shall initially be Adele Oliva, to attend all meetings of the Company Board and any committees or sub-committees thereof in
a nonvoting observer capacity (a “Observer”) and Ampersand shall have right to designate two (2) Observers,
who shall initially be Herb Hooper and Laurence McCarthy; provided, that the Observers can be excluded from any meeting of any
committee or sub-committee of the Company Board at the sole discretion of such committee or sub-committee for any reason.

 

6.3
Compensation; D&O Insurance; Indemnification. The Company shall reimburse each Investor Director and Observer for his
or her reasonable out-of-pocket expenses incurred for the purpose of attending each meeting of the Company Board or any committee
thereof in accordance with the Company’s reimbursement policy in effect from time to time for non-employee directors (such
policy being deemed to apply to an Observer as if he or she were a member of the Company Board). Each Investor Director shall
be entitled to the same benefits and other rights (other than compensation) provided to any other non-executive director, including
benefits and coverage under any director and officer insurance policy maintained by the Company. Promptly following the appointment
or election of any Investor Director, the Company and such Investor Director shall enter into an indemnification agreement on
terms substantially similar to the terms of indemnification agreements that the Company has entered into with any other non-executive
director. The Company shall enter into an indemnification agreement at least as favorable as the indemnification agreements entered
into with any other non-executive director after the Closing Date with any other individual that becomes an Investor Director,
if and as applicable.

 

    	17

    	 

    

 

6.4
Information Rights. From and after the Closing Date, the Company shall deliver to the Investor Directors and Observers,
as applicable, and the Investors (for the benefit of the Investors) copies of all written information (including, without limitation,
board packages, notices, minutes, consents, budgets, business plans, financial forecasts, financial statements (audited or unaudited,
with or without footnotes), operating reports and any other materials to the extent and in the manner and form provided to the
Company Board or any committee or sub-committee thereof or in any periodic information required to be delivered to any lender
to the Company or any of its subsidiaries, in each case, at the same time such information is provided to the Company Board (or
any committee or sub-committee thereof) or any such lender). The Investor Directors, Observers and/or Investor may, in its, his
or her sole discretion, request that delivery of such written information and materials not be provided to it, him or her at any
time; provided, however, that refusal of any one or more deliveries shall not be deemed to be an ongoing waiver or amendment of
the Company’s obligations and/or each of the Investor Director’s, Observer’s or Investor’s rights pursuant
to this Section 6.5.

 

6.5
Confidentiality. Ampersand agrees to keep confidential “Evaluation Material” (as defined in the Ampersand Confidentiality
Agreement) and 1315 Capital agrees to keep confidential “Confidential Information” (as defined in the 1315 Capital
Confidentiality Agreement) received prior to the date hereof and all proprietary and all non-public information regarding the
Company and its subsidiaries received pursuant to Section 6.5 (the “Confidential Information”),
and in each case not to disclose or reveal any such Confidential Information to any Person without the prior written consent of
the Company; provided, however, that Confidential Information may be disclosed by any Investor to its members, directors, managers,
officers, employees, debt financing sources, potential purchasers of Equity Securities from any Investor Party with respect to
transfers that would be permitted pursuant to Section 8.3, consultants, agents, advisors and representatives, including
the Investor Directors and Observers (collectively, “Permitted Representatives”) who need to know such
Confidential Information for the purpose of evaluating, monitoring or taking any other action with respect to the investment by
any Investor in any Series B Shares or Common Shares issued or issuable upon conversion of any Series B Shares pursuant to the
Certificate of Designation, and agree to cause such Permitted Representatives to observe the terms of this Section 6.6;
provided, that nothing herein shall prevent any Investor or any Permitted Representative from disclosing any Confidential
Information that (1) is or becomes generally available to the public other than as a result of any act or omission by an Investor
or such Permitted Representative in violation of this Section 6.6, (2) was available to any Investor or Permitted Representative
on a non-confidential basis prior to disclosure to any Investor or Permitted Representative by the Company or its representatives,
(3) becomes available to any Investor or Permitted Representatives from a source other than the Company or its representatives
when such source is entitled, to the knowledge of such Investor, to make such disclosure without violating any fiduciary duty
or any non-disclosure or confidentiality agreement, or (4) is required to be disclosed by law, rule or regulation (provided;
that prior to such disclosure, the applicable Investor shall, unless prohibited by law, rule, regulation or order, promptly notify
the Company of any such disclosure, use reasonable efforts to limit the disclosure requirements of such law or order, and maintain
the confidentiality of such information to the maximum extent permitted by law, rule or regulation). If any Investor or Permitted
Representative is requested or required (by oral questions, interrogatories, requests for information, subpoena, civil investigative
demand or similar process) to disclose any Confidential Information, it is agreed that such Investor will provide the Company
with prompt written notice of such request(s) so that the Company may seek (at the Company’s sole cost) an appropriate protective
order or other appropriate remedy and/or waive the Investor’s compliance with this Section 6.6. If, failing the entry
of a protective order or the receipt of a waiver hereunder, any Investor or Permitted Representative is, after consultation with
outside counsel, compelled to disclose Confidential Information, such Investor or Permitted Representative may disclose only that
portion of such information that in the opinion of Investor’s counsel is legally required without liability hereunder; provided,
that such Investor agrees to use commercially reasonable efforts to obtain, at the Company’s sole expense, assurance that
confidential treatment will be accorded such information, including, by cooperating with the Company to obtain an appropriate
protective order or other reliable assurance that confidential treatment will be accorded the Confidential Information.

 

    	18

    	 

    

 

7.
RIGHTS TO PURCHASE.

 

7.1
Right to Participate in Certain Sales of Additional Securities.

 

7.1.1
For so long as any shares of Registrable Securities remain outstanding, the Company agrees that it will not (and that it will
cause its subsidiaries not to) sell or issue any shares of Capital Stock or Equity Securities, in each case, unless (x) the Company
first submits a written notice (a “Pre-Emptive Right Notice”) to the Investors (for the benefit of the
Investor Parties) setting forth in reasonable detail (A) the designation and all of the terms and provisions of the securities
proposed to be issued (the “Proposed Securities”), including, to the extent applicable, the voting powers,
preferences and relative participating, optional or other special rights, and the qualification, limitations or restrictions thereof
and interest rate and maturity; (B) the price, timing (which shall be at least three (3) but no more than six (6) Business Days
after the delivery or deemed delivery of such Pre-Emptive Right Notice to the Investor) and other terms of the proposed sale of
such Proposed Securities; and (C) the amount of such Proposed Securities proposed to be issued; provided, that following the delivery
of such notice, the Company shall deliver to the Investors (for the benefit of the Investor Parties) any such information the
Investors may reasonably request in order to evaluate the proposed issuance, (y) it offers to issue and sell to the Investor Parties,
on such terms as the Proposed Securities are issued and upon full payment by the Investor Parties, the lesser of (i) fifty percent
(50%) of the Proposed Securities (to be allocated among the Investor Parties in proportion to their respective levels of ownership
of Series B Shares as of the date of the Pre-Emptive Rights Notice) or (ii) the percentage of the Proposed Securities equal to
the aggregate Participation Portions of the Investor Parties (to be allocated among the Investor Parties in proportion to their
respective levels of ownership of Series B Shares as of the date of the Pre-Emptive Rights Notice); provided, however,
that, subject to compliance with the terms and conditions set forth in Section 7.1.5, the Company shall not be required
to offer to issue or sell to the Investor Parties the portion of the Proposed Securities that would require the Company to obtain
stockholder approval in respect of the issuance of any Proposed Securities to the Investor Parties under Nasdaq Marketplace Rule
5635 unless such approval has been obtained (provided, further, however, that the Company shall still be
obligated to provide written notice of such proposed issuance to the Investors (for the benefit of the Investor Parties), which
notice shall include a description of the Proposed Securities (including the number thereof) that would require stockholder approval
in respect of the issuance thereof).

 

7.1.2
The Investor Parties will have the option, exercisable by written notice delivered by the Investors (on behalf of the Investor
Parties) to the Company, to accept the Company’s offer and commit to purchase any or all of the Proposed Securities offered
to be sold by the Company to such Investor Parties, which notice must be given prior to the later of (x) five (5) Business Days
after receipt of such notice from the Company and (y) two (2) Business Days prior to the proposed issuance date set forth in the
Pre-Emptive Right Notice (the “Pre-Emptive Right Lapse Time”). If the Company offers two (2) or more
securities as a unit to all other participants in the offering, the Investor Parties will be given the same choice as provided
to other participants in the offering. The closing of the exercise of such subscription right shall take place simultaneously
with the closing of the sale of the Proposed Securities giving rise to such subscription right; provided, however, that
the closing of any purchase by any such Investor Party may be extended beyond the closing of the sale of the Proposed Securities
giving rise to such preemptive right to the extent necessary to (i) obtain required approvals from any Governmental Authority
or (ii) permit one or more Investor Parties to receive proceeds from calling capital pursuant to commitments made by its (or its
affiliated investment funds’) limited partners. Upon the expiration of the offering period described above, the Company
will be free to sell such Proposed Securities that the Investor Parties have not elected to purchase during the 60 days following
such expiration on terms and conditions no more favorable to the purchasers thereof than those offered to the Investor Parties
in the Pre-Emptive Right Notice delivered in accordance with Section 7.1.1. Any Proposed Securities offered or sold by
the Company after such 60-day period must be reoffered to issue or sell to the Investor Parties pursuant to this Section 7.1;
provided that, subject to compliance with the terms and conditions set forth in Section 7.1.5, the Company shall
not be required to reoffer to the Investor Parties the portion of the Proposed Securities that would require the Company to obtain
stockholder approval in respect of the issuance of any Proposed Securities under the under Nasdaq Marketplace Rule 5635 unless
such approval has been obtained. 

 

    	19

    	 

    

 

7.1.3
The election by any Investor Party not to exercise its pre-emptive rights under this Section 7.1 in any one instance shall
not affect its right as to any subsequent proposed issuance.

 

7.1.4
In the case of an issuance subject to this Section 7.1 for consideration in whole or in part other than cash, including
securities acquired in exchange therefor, the consideration other than cash shall be deemed to be the “Fair Market Value”
(as defined in the Certificate of Designation) thereof.

 

7.1.5
In the event that the Company is not required to offer or reoffer to an Investor Party any Proposed Securities because such issuance
would require the Company to obtain stockholder approval in respect of the issuance of any Proposed Securities under Nasdaq Marketplace
Rule 5635, the Company shall, upon the reasonable request of the Investors delivered to the Company in writing at or before the
Pre-Emptive Right Lapse Time, at the Investors’ election (acting in its sole discretion):

 

(a)
consider and discuss in good faith modifications proposed by the Investors to the terms and conditions of such portion of the
Proposed Securities which would otherwise be issued to the Investor Party such that the Company would not be required to obtain
stockholder approval in respect of the issuance of such Proposed Securities as so modified; and/or;

 

(b)
take such actions as may be reasonably necessary to seek stockholder approval in respect of the issuance of any Proposed Securities
to the Investor Parties, including without limitation, calling a special meeting of the Company’s stockholders to vote on
(and including in the proxy statement related thereto) a proposal to authorize and approve potential equity issuances by the Company
upon exercise of the Investor Parties’ rights pursuant to Section 7 which occur prior to the seven-year anniversary
of such special meeting and a recommendation by the Company Board in favor of the approval of such proposal (providing the highest
level of support for the approval of such proposal as the Company Board provides to any other proposal included in either such
proxy statement or the proxy statement for the preceding year’s annual meeting of stockholders).

 

7.2
Exceptions. Notwithstanding the foregoing, the right to purchase granted to the Investor Parties under this Section
7 shall be inapplicable with respect to the issuance of Exempted Securities. The Company and the Investors also severally
agree that, with respect to an underwritten offering of securities that is consummated within one year of the Closing Date, to
the extent the offer and sale of any securities in such underwritten offering to any Investor Party pursuant to this Section
7 would not comply with Rule 2010 of the Financial Industry Regulatory Authority Manual or applicable rules and regulations
of the Commission, then the Company shall not be required to make such an offer and sale in such underwritten offering to any
Investor Party pursuant to this Section 7. In such event, the Company agrees that it will cooperate with the Investor Parties
and will promptly take all actions to effect the offer and sale of securities to the Investor Parties in an alternative manner
that complies with Rule 2010 of the Financial Industry Regulatory Authority Manual or applicable rules and regulations of the
Commission so that the intents and purposes of this Section 7 are effectuated, including without limitation by offering the Investor
Parties securities in a private transaction that provide the Investor Parties the opportunity to maintain their respective proportional
stock ownership in the Company on a fully-diluted basis.

 

    	20

    	 

    

 

8.
COVENANTS.

 

8.1
Standstill. The Investors agree that during the Standstill Period, without the prior written approval of the Company or
the Company Board, or as otherwise expressly permitted or contemplated by this Agreement (including Section 7) or the Certificate
of Designation, each Investor will not and will cause its respective Affiliates not to acquire beneficial ownership of any securities
(including in derivative form) of the Company, in each case excluding (x) the Series B Shares purchased or issued directly from
the Company or Common Shares issuable upon conversion of the Series B Shares, and (y) any Capital Stock or other Equity Securities
of the Company pursuant to or in accordance with the Certificate of Designation or Section 7 hereof.

 

8.2
Short Sales Prohibited. The Investors shall not engage, directly or indirectly, in any transactions in the Company’s
securities (including, without limitation, any Short Sales involving the Company’s securities) during the period from the
date hereof until the earlier of (i) the consummation of a Deemed Liquidation (as defined in the Certificate of Designation);
and (ii) the date that Investor Parties do not own any Series B Shares or Common Shares issuable upon conversion of the Series
B Shares.

 

8.3
Lock-Up. The Investors agree that during the Lock-Up Period, the Investors shall not transfer any Common Shares issuable
upon conversion of the Series B Shares, except as part of a pledge by an Investor of the equity securities it acquires in any
portfolio company that is made to secure indebtedness existing as of the date hereof for borrowed money incurred in connection
with on-call commitments of such Investor’s limited partners (a “Permitted Pledge”) or to any
Affiliate of such Investor.

 

8.4
Investor Consent Rights. For so long as any shares of the Series B Shares remain outstanding, the following actions may
only be taken by the Company or any of its direct or indirect subsidiaries with the written consent of Investors representing
at least seventy-five percent (75%) of the outstanding Series B Shares:

 

8.4.1
amend, waive, alter or repeal the preferences, rights, privileges or powers of the Series B Shares;

 

8.4.2
amend, alter or repeal any provision of the Certificate of Designation in a manner that is adverse to the holders of Series B
Shares;

 

8.4.3
authorize, create or issue any equity securities senior to or pari passu with either series of the Series B Shares; or

 

8.4.4
increase or decrease the number of directors constituting the Company Board.

 

    	21

    	 

    

 

8.5
Additional Investor Consent Rights. For so long as at least thirty percent (30%) of the Series B Shares outstanding as
of the Closing Date remains outstanding (as equitably adjusted for any stock split, reverse stock split, recapitalization or similar
event with respect to the Common Shares), the following actions may only be taken by the Company or any of its direct or indirect
subsidiaries with the written consent with the consent of Investors representing at least seventy-five percent (75%) of the outstanding
shares of Series B Shares:

 

8.5.1.1
(a) authorize, create or issue any debt securities for borrowed money or funded debt pursuant to which the Company or any of its
direct or indirect subsidiaries issues shares, warrants or any other convertible security in the same transaction or a series
of related transactions; or (b) authorize, create or issue any debt securities for borrowed money or funded debt pursuant to which
the Company or any of its direct or indirect subsidiaries does not issue shares, warrants or any other convertible security in
the same transaction or a series of related transactions exceeding $4.5 million initially (the “Debt Threshold”),
excluding, however: (i) any capitalized and operating leases entered into by the Company or its direct or indirect subsidiaries
in the ordinary course of business consistent with past practice and (ii) any debt incurred by the Company pursuant to the terms
of the Company’s existing term loan and credit facility with Silicon Valley Bank; provided, that if the aggregate consolidated
revenue recognized by the Company and its direct or indirect subsidiaries (the “Combined Revenue”) as
reported by the Company on Form 10-K for any fiscal year ending after the Closing Date exceeds $45 million dollars, the Debt Threshold
for the following fiscal year shall increase to an amount equal to: (i) ten percent (10%); multiplied by (ii) the Combined Revenue
as reported by the Company on Form 10-K for the previous fiscal year;

 

8.5.1.2
merge with or acquire all or substantially all of the assets of one or more other companies or entities with a value in excess
of $20 million (the “Acquisition Threshold”); provided, that the Acquisition Threshold shall increase
on a straight line basis to an amount up to $40 million, but in no event greater than $40 million, to the extent Combined Revenue
for the then-most recently completed quarterly period as reported by the Company on Form 10-K or Form 10-Q, as applicable, falls
between the Combined Revenue for the Company’s fiscal quarter ended on September 30, 2019, and 100% greater than the Combined
Revenue for the Company’s fiscal quarter ended on September 30, 2019;

 

8.5.1.3
materially change the nature of the business of the Company or any of its direct or indirect subsidiaries as it is proposed to
be conducted as of the Closing Date;

 

8.5.1.4
consummate any Liquidation (as defined in the Certificate of Designation);

 

8.5.1.5
transfer, by sale, exclusive license or otherwise, material intellectual property rights of the Company or any of its direct or
indirect subsidiaries, other than licenses, transfers or sales of products accomplished in the ordinary course of business consistent
with past practice;

 

8.5.1.6
declare or pay any cash dividend or make any cash distribution on any equity interests of the Company other than the Series B
Shares;

 

8.5.1.7
repurchase or redeem any shares of capital stock of the Company, except for: (a) the redemption of the Series B Shares pursuant
to Section 5(d) of the Certificate of Designation; or (b) repurchases of Common Shares under agreements previously approved by
the Company Board with employees, consultants, advisors or others who performed services for the Company or any direct or indirect
subsidiary in connection with the cessation of such employment or service;

 

8.5.1.8
(a) incur any additional individual debt, indebtedness for borrowed money or other additional liabilities pursuant to which the
Company or any of its direct or indirect subsidiaries issues shares, warrants or any other convertible security in the same transaction
or a series of related transactions; or (b) incur any individual debt, indebtedness for borrowed money or other liabilities pursuant
to which the Company or any of its direct or indirect subsidiaries does not issue shares, warrants or any other convertible security
in the same transaction or a series of related transactions in excess of the Debt Threshold (in each case, excluding: (i) any
capitalized and operating leases entered into by the Company or its direct or indirect subsidiaries in the ordinary course of
business consistent with past practice; (ii) any debt incurred by the Company pursuant to the terms of the Company’s existing
term loan and credit facility with Silicon Valley Bank; and (iii) any purchase money financing in connection with the acquisition
of equipment or otherwise);

 

    	22

    	 

    

 

8.5.1.9
change any accounting methods or practices of the Company or any of its direct or indirect subsidiaries, except for those changes
required by GAAP or applicable regulatory agencies or authorities, including but not limited to the Securities and Exchange Commission
and the Financial Accounting Standards Board, in each case, as consented to by the Company’s independent auditors; or

 

8.5.1.10
conduct a public offering of Common Shares registered with the Securities and Exchange Commission, including any at-the-market
offering of the Company’s Common Shares.

 

8.6
Tax Treatment. The Company agrees that, except as otherwise required pursuant to a change in law applicable to the Series
B Shares or a final determination (as defined in Section 1313(a) of the Code), (a) it will not treat the Series B Shares as “preferred
stock” for purposes of Section 305 of the Code and (b) it will not treat any accrued or accumulated but undeclared dividends
on the Series B Shares as a distribution pursuant to Section 305(c) of the Code.

 

8.7
Section 16 Matters. If the Company becomes a party to a consolidation, merger or other similar transaction that may result
in Investor, any other Investor Party and/or any Investor Director or Observer being deemed to have made a disposition of equity
securities of the Company or derivatives thereof for purposes of Section 16 of the Exchange Act, and if such Investor Director
is serving on the Company Board at such time or has served on the Company Board during the preceding six months (or if the Observers
are serving in its capacity as such or has served in such capacity during the preceding six months): (i) the Company Board will
pre-approve such disposition of equity securities of the Company or derivatives thereof for the express purpose of exempting the
Investor Parties’, the Investor Director’s and the Observer’s interests (for the Investor Parties and/or Observers,
to the extent any Investor Party or the Observers may be deemed to be “directors by deputization”) in such transaction
from Section 16(b) of the Exchange Act pursuant to Rule 16b-3 thereunder and (ii) if the transaction involves (A) a merger or
consolidation to which the Company is a party and Common Shares or Series B Shares are, in whole or in part, converted into or
exchanged for equity securities of a different issuer, (B) a potential acquisition by any Investor Party and/or any Investor Director
or Observer of equity securities of such other issuer or derivatives thereof and (C) an Affiliate or associate or other designee
of any Investor Party will serve on the board of directors (or its equivalent) of such other issuer, then if the Company requires
that the other issuer pre-approve any acquisition of equity securities or derivatives thereof for the express purpose of exempting
the interests of any director or officer of the Company or any of its subsidiaries in such transactions from Section 16(b) of
the Exchange Act pursuant to Rule 16b-3 thereunder, the Company shall require that such other issuer pre-approve any such acquisitions
of equity securities or derivatives thereof for the express purpose of exempting the interests of the Investor Parties, the Investor
Directors and the Observers (for the Investor Parties and/or Observers, to the extent such persons may be deemed to be “directors
by deputization” of such other issuer) in such transactions from Section 16(b) of the Exchange Act pursuant to Rule 16b-3
thereunder.

 

8.8
Corporate Actions. At any time that any Series B Share is outstanding, the Company shall:

 

8.8.1
take all action necessary to at all times have authorized, and reserved for the purpose of issuance from and after the Closing
Date, the number of Common Shares issuable upon conversion of the Series B Shares in accordance with the terms of the Certificate
of Designation; and

 

8.8.2
not effect any voluntary deregistration under the Exchange Act or any voluntary delisting with the Nasdaq Stock Market in respect
of the Common Shares other than in connection with a Deemed Liquidation (as defined in the Certificate of Designation) pursuant
to which the Company agrees to satisfy, or will otherwise cause the satisfaction, in full of its obligations under the Certificate
of Designation.

 

    	23

    	 

    

 

8.9
Voting. Each Investor shall vote all voting securities of the Company owned by such Investor, or over which such Investor
has voting control, in favor of the election of any individual who is nominated by the Company’s Nominating and Corporate
Governance Committee to serve as a director on the Company Board; provided that nothing in this Section 8.9 shall
prevent an Investor from exercising its rights to designate and elect the Investor Directors as contemplated by Section 6.1.
Each Investor’s obligations pursuant to this Section 8.9 shall terminate if such Investor is no longer entitled to
designate or elect an Investor Director pursuant to Section 6.1.

 

9.
MISCELLANEOUS.

 

9.1
Other Registration Rights and Arrangements. The Company represents and warrants that no person, other than the holders
of the Registrable Securities, has any right to require the Company to register any of the Company’s share capital for sale
or to include the Company’s share capital in any registration filed by the Company for the sale of shares for its own account
or for the account of any other person. The Company shall not hereafter enter into any agreement with respect to its securities
which is inconsistent with or violates the rights granted to the holders of Registrable Securities in this Agreement and in the
event of any conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.

 

9.2
Assignment; No Third Party Beneficiaries. This Agreement and the rights, duties and obligations of the Company hereunder
may not be assigned or delegated by the Company in whole or in part. Subject to Section 8.3, this Agreement and the rights,
duties and obligations of the holders of Registrable Securities hereunder may be freely assigned or delegated by such holder of
Registrable Securities in conjunction with and to the extent of any permitted transfer of Registrable Securities by any such holder;
provided, that Sections 6.1 – 6.5, 7, 8.4, 8.5, 8.6, 8.7 and 8.9
shall not be transferable or assignable to the transferee of Registrable Securities that received such Registrable Securities
upon foreclosure of a Permitted Pledge. This Agreement and the provisions hereof shall be binding upon and shall inure to the
benefit of each of the parties hereto and their respective successors and assigns and the holders of Registrable Securities and
their respective successors and permitted assigns. This Agreement is not intended to confer any rights or benefits on any persons
that are not party hereto other than as expressly set forth in Section 4 and this Section 9.2. The rights of a holder
of Registrable Securities under this Agreement may be transferred by such a holder to a transferee; provided, however,
that such transferee has executed and delivered to the Company a properly completed agreement to be bound by the terms of this
Agreement substantially in form attached hereto as Exhibit A (an “Addendum Agreement”), and the
transferor shall have delivered to the Company no later than thirty (30) days following the date of the transfer, written notification
of such transfer setting forth the name of the transferor, the name and address of the transferee, and the number of Registrable
Securities so transferred. The execution of an Addendum Agreement shall constitute a permitted amendment of this Agreement.

 

    	24

    	 

    

 

9.3
Notices. All notices, demands, requests, consents, approvals or other communications (collectively, “Notices”)
required or permitted to be given hereunder or which are given with respect to this Agreement shall be in writing and shall be
deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via email
(provided the sender does not receive a machine-generated rejection of transmission) at the email address specified in this Section
9.3 prior to 5:00 P.M., New York City time, on a Business Day, (b) the next Business Day after the date of transmission, if
such notice or communication is delivered via email at the email address specified in this Section 9.3 on a day that is
not a Business Day or later than 5:00 P.M., New York City time, on any Business Day, (c) the Business Day following the date of
mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual
receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as
follows (or to such other address or email address as such party shall have specified most recently by written notice):

 

If
to the Company:

 

Interpace
Biosciences, Inc.

Morris
Corporate Center 1, Building C

300
Interpace Parkway, Parsippany, NJ 07054

Attention:
Jack E. Stover, President and CEO

Email:
jstover@interpace.com

 

With
a copy to:

 

Pepper
Hamilton LLP

620
Eighth Avenue, 37th Floor

New
York Times Building

New
York, NY 10018

Attention:
Merrill M. Kraines, Esquire

Email:
krainesm@pepperlaw.com

 

If
to 1315 Capital:

 

1315
Capital II, L.P.

2929
Walnut Street, Suite 1240

Philadelphia,
PA 19104

Attention:
Adele C. Oliva, Founding Partner

Email:
adele.oliva@1315capital.com

 

With
a copy to:

 

Morgan,
Lewis & Bockius LLP

1701
Market Street

Philadelphia,
PA 19103-2921

Attention:
Joanne R. Soslow, Esquire

Email:
joanne.soslow@morganlewis.com

 

If
to Ampersand:

 

Ampersand
2018 Limited Partnership

c/o
Ampersand Capital Partners

55
William Street, Suite 240

Wellesley,
MA 02481

Attention:
Dana L. Niles, Chief Operating Partner

Email:
dln@ampersandcapital.com

 

    	25

    	 

    

 

With
a copy to:

 

Goodwin
Procter LLP

100
Northern Avenue

Boston,
MA 02210

Attention:
James T. Barrett, Esq., and Jocelyn Arel, Esq.

Email:
JBarrett@goodwinlaw.com and JArel@goodwinlaw.com

 

9.4
Severability; Amendments; Waivers. This Agreement shall be deemed severable, and the invalidity or unenforceability of
any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision
hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall
be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible
that is valid and enforceable. The provisions of this Agreement may be amended, modified or supplemented, and waivers or consents
to departures from the provisions hereof may be given, only with the written agreement of holders holding seventy-five percent
(75%) of the Registrable Securities covered hereby.

 

9.5
Governing Law; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware,
without regard to the principles of conflicts of law thereof that would result in the application of any law other than the laws
of the State of Delaware. Each party agrees that all proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Agreement (whether brought against a party hereto or its respective Affiliates, employees or
agents) shall be commenced exclusively in the state and federal courts sitting in the City of Wilmington in the State of Delaware.
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of such courts for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives,
and agrees not to assert in any proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
or that such proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal
service of process and consents to process being served in any such proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY
WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

9.6
Specific Enforcement. The parties acknowledge and agree that (a) the parties shall be entitled to an injunction or injunctions,
specific performance or other equitable relief to enforce specifically the terms and provisions hereof in the courts described
in Section 9.5 without proof of damages or otherwise, this being in addition to any other remedy to which they are entitled
under this Agreement and (b) the right of specific enforcement is an integral part of this Agreement and without that right, neither
the Company nor the Investors would have entered into this Agreement. The parties hereto agree not to assert that a remedy of
specific enforcement is unenforceable, invalid, contrary to law or inequitable for any reason, and agree not to assert that a
remedy of monetary damages would provide an adequate remedy or that the parties otherwise have an adequate remedy at law. The
parties hereto acknowledge and agree that any party seeking an injunction or injunctions to prevent breaches of this Agreement
and to enforce specifically the terms and provisions of this Agreement in accordance with this Section 9.6 shall not be
required to provide any bond or other security in connection with any such order or injunction.

 

9.7
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all
of which taken together shall constitute one and the same instrument.

 

9.8
Construction; Interpretation. The headings herein are for convenience only, do not constitute a part of this Agreement
and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to
be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against
any party. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. Unless otherwise indicated
to the contrary herein by the context or use thereof: (i) the words, “herein,” “hereto,” “hereof”
and words of similar import refer to this Agreement as a whole, including the Schedules and exhibits, and not to any particular
section, subsection, paragraph, subparagraph or clause contained in this Agreement; (ii) masculine gender shall also include the
feminine and neutral genders, and vice versa; (iii) words importing the singular shall also include the plural, and vice versa;
(iv) the words “include,” “includes” or “including” shall be deemed to be followed by the
words “without limitation”; (v) financial terms shall have the meanings given to such terms under GAAP unless otherwise
specified herein; (vi) references to “$” or “dollar” or “US$” shall be references to United
States dollars; (vii) where the context permits, the use of the term “or” will be non-exclusive and equivalent to
the use of the term “and/or”; (viii) the word “extent” in the phrase “to the extent” shall
mean the degree to which a subject or other thing extends, and such phrase shall not mean simply “if”; and (ix) if
any action under this Agreement is required to be done or taken on a day that is not a Business Day or on which a government office
is not open with respect to which a filing must be made, then such action shall be required to be done or taken not on such day
but on the first succeeding Business Day thereafter.

 

9.9
Entire Agreement. This Agreement and the Securities Purchase Agreement (including all agreements entered into pursuant
hereto and thereto and all certificates and instruments delivered pursuant hereto or thereto) constitute the entire agreement
of the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, representations,
understandings, negotiations and discussions between the parties, whether oral or written.

 

[Signature
Page Follows]

 

    	26

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered by their duly authorized representatives
as of the date first written above.

 

	 	COMPANY:
	 	 	 
	 	INTERPACE BIOSCIENCES, INC.
	 	 	 
	 	By:	/s/
    Jack E. Stover
	 	Name:	Jack
    E. Stover
	 	Title:	President
    & Chief Executive Officer

 

[Remainder
of Page Intentionally Left Blank]

 

Signature
Page to Investor Rights Agreement

 

    	 

    	 

    

 

	 	INVESTORS:
	 	 	 
	 	Ampersand 2018 Limited Partnership
	 	 	 
	 	By:
    	AMP-18
    Management Company Limited Partnership, its General Partner
	 	 	 
	 	By:
    	AMP-18
    MC LLC, its General Partner

 

	 	By:	/s/
    Herbert H. Hooper
	 	Name:	Herbert
    H. Hooper
	 	Title:	Managing
    Member

 

	 	1315 CAPITAL II, L.P.
	 	 	 
	 	By:	1315
    Capital Management II, LLC, 
	 	 	its
    General Partner

 

	 	By:	/s/
    Adele C. Oliva
	 	Name:	Adele
    C. Oliva
	 	Title:	Managing
    Member

 

Signature
Page to Investor Rights Agreement

 

    	 

    	 

    

 

EXHIBIT
A

 

Addendum
Agreement

 

This
Addendum Agreement (“Addendum Agreement”) is executed on __________________, 20___, by the undersigned
(the “New Holder”) pursuant to the terms of that certain Amended and Restated Investor Rights Agreement,
dated as of January 15, 2020 (the “Agreement”), by and among the Company and the Investors identified
therein, as such Agreement may be amended, supplemented or otherwise modified from time to time. Capitalized terms used but not
defined in this Addendum Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution
of this Addendum Agreement, the New Holder agrees as follows:

 

1.
Acknowledgment. New Holder acknowledges that New Holder is acquiring certain Common Shares of the Company (the “Shares”)
[or other equity securities of the Company that are convertible, exercisable or exchangeable for Common Shares of the Company
(the “Convertible Securities”)] as a transferee of such Shares [or Convertible Securities] from a party
in such party’s capacity as a holder of Registrable Securities under the Agreement, and after such transfer, New Holder
shall be considered an “Investor” and a holder of Registrable Securities for all purposes under the Agreement.

 

2.
Agreement. New Holder hereby (a) agrees that the Shares [or Convertible Securities] shall be bound by and subject to the
terms of the Agreement and (b) adopts the Agreement with the same force and effect as if the New Holder were originally a party
thereto.

 

3.
Notice. Any notice required or permitted by the Agreement shall be given to New Holder at the address or facsimile number
listed below New Holder’s signature below.

 

	NEW HOLDER:	 	ACCEPTED AND AGREED:
	 	 	 	 	 
	Print Name:	 	INTERPACE BIOSCIENCES, INC.
	 	 	 	 	 
	By:	           	 	By:	                 

 

    	 

    	 

    

 

EXHIBIT
B

 

SELLING
STOCKHOLDER NOTICE AND QUESTIONNAIRE

 

The
undersigned holder of shares of the Series B Convertible Preferred Stock, par value $0.01 per share, of Interpace Biosciences,
Inc., a Delaware corporation (the “Company”), is a party to that certain Amended and Restated Investor Rights
Agreement, dated as of January 15, 2020, by and among the Company, 1315 Capital II, L.P., a Delaware limited partnership,
Ampersand 2018 Limited Partnership, a Delaware limited partnership (the “Agreement”), and understands that
the Company is obligated to file with the Securities and Exchange Commission a registration statement (the “Registration
Statement”) for the registration of the Registrable Securities in accordance with the terms of the Agreement. All capitalized
terms not otherwise defined herein shall have the meanings ascribed thereto in the Agreement. The undersigned has agreed to complete,
execute and deliver this Questionnaire to the Company pursuant to Section 3.4 of the Agreement.

 

In
order to sell or otherwise dispose of any Registrable Securities pursuant to the Registration Statement, a holder of Registrable
Securities generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as
so supplemented, the “Prospectus”), deliver the Prospectus to purchasers of Registrable Securities (including
pursuant to Rule 172 under the Securities Act). Holders must complete and deliver this Notice and Questionnaire in order to be
named as selling stockholders in the Prospectus. Holders of Registrable Securities who do not complete, execute and return
this Notice and Questionnaire within ten (10) Business Days following either (A) any Investor’s delivery of a notice for
Demand Registration, (B) the Company’s delivery of a notice for Piggy-Back Registration or (C) a request from the Company
in connection with the filing of a Resale Shelf Registration Statement pursuant to Section 2.3 of the Agreement (1) will
not be named as selling stockholders in the Registration Statement or the Prospectus and (2) may not use the Prospectus for resales
of Registrable Securities.

 

Certain
legal consequences arise from being named as a selling stockholder in the Registration Statement and the Prospectus. Holders of
Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not
named as a selling stockholder in the Registration Statement and the Prospectus.

 

NOTICE

 

The
undersigned holder (the “Selling Stockholder”) of Registrable Securities hereby gives notice to the Company
of its intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item (3), unless otherwise
specified in Item (3), pursuant to the Registration Statement. The undersigned, by signing and returning this Notice and Questionnaire,
understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire and the Agreement.

 

The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate
and complete:

 

    	 

    	 

    

 

 QUESTIONNAIRE

 

1.
Name.

 

	(a)	Full Legal Name of Selling Stockholder:
	 	 
	 	

 

	(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities Listed in Item 3 below
are held:
	 	 

 

	(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power
to vote or dispose of the securities covered by the questionnaire):
	 	 

 

2.
Address for Notices to Selling Stockholder:

 

	 
	 
	 
	Telephone: ____________________________________________________________________________
	Fax:  _________________________________________________________________________________
	Contact
    Person: ________________________________________________________________________
	E-mail
    address of Contact Person:______________________________________________

 

3.
Beneficial Ownership of Registrable Securities Issuable Pursuant to the Purchase Agreement:

 

	 	(a)	Type
    and Number of Registrable Securities beneficially owned and issued pursuant to the Agreement:
	 	 	 
	 	 	
	 	 	
	 	 	

 

 

	 	(b)	Number
    of shares of Common Shares to be registered pursuant to this Notice for resale:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

    	 

    	 

    

 

4.
Broker-Dealer Status:

 

	 	(a)
    	Are
    you a broker-dealer?

 

	Yes[  ]
    	No[  ]
    

 

	 	(b)	If
    “yes” to Section 4(a), did you receive your Registrable Securities as compensation for investment banking
    services to the Company?

 

	Yes[  ]
    	No[  ]
    

 

	Note:
    	If
    no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

 

	 	(c)
    	Are
    you an affiliate of a broker-dealer?

 

	Yes[  ]
	No[  ]
    

 

	 	Note:	If
    yes, provide a narrative explanation below:

 

	 	 	 
	 	 	 
	 	 	 

 

	 	(d)	If
    you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course
    of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings,
    directly or indirectly, with any person to distribute the Registrable Securities?

 

	Yes[  ]
	No[  ]
    

 

	 	Note:	If
    no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

 

5.
Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder.

 

Except
as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company
other than the Registrable Securities listed above in Item 3.

 

Type
and amount of other securities beneficially owned:

 

		__________________________________________________________________________________

 

		_______________________________________________________________________________

 

6.
Relationships with the Company:

 

Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners
of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship
with the Company (or its predecessors or affiliates) during the past three years.

 

    	 

    	 

    

 

	 	State
    any exceptions here:

 

	 	 
	 	 

 

 ***********

 

The
undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur
subsequent to the date hereof and prior to the effective date of any applicable Registration Statement. All notices hereunder
and pursuant to the Agreement shall be made in writing, by hand delivery, confirmed or facsimile transmission, first-class mail
or air courier guaranteeing overnight delivery at the address set forth below. In the absence of any such notification, the Company
shall be entitled to continue to rely on the accuracy of the information in this Notice and Questionnaire.

 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items (1) through
(6) above and the inclusion of such information in the Registration Statement and the Prospectus. The undersigned understands
that such information will be relied upon by the Company in connection with the preparation or amendment of any such Registration
Statement and the Prospectus.

 

By
signing below, the undersigned acknowledges that it understands its obligation to comply, and agrees that it will comply, with
the provisions of the Exchange Act and the rules and regulations thereunder. The undersigned also acknowledges that it understands
that the answers to this Questionnaire are furnished for use in connection with Registration Statements filed pursuant to the
Registration Rights Agreement and any amendments or supplements thereto filed with the Commission pursuant to the Securities Act.

 

I
confirm that, to the best of my knowledge and belief, the foregoing statements (including without limitation the answers to this
Questionnaire) are correct.

 

IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Questionnaire to be executed and delivered either in
person or by its duly authorized agent.

 

	Dated:
____________________________    	Beneficial Owner: ________________________
	 	 	 
	 	By:	                                        
	 	Name:	 
	 	Title:Exhibit
10.2

 

INTERPACE
BIOSCIENCES, INC.

 

INDEMNIFICATION
AGREEMENT

 

This
Indemnification Agreement (“Agreement”) is effective as of January __, 2020, by and between Interpace
Biosciences, Inc., a Delaware corporation (the “Company” or “Interpace”),
and [ ] (“Indemnitee”).

 

WHEREAS,
highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities
unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims
and actions against them arising out of their service to and activities on behalf of the corporation;

 

WHEREAS,
in order to induce Indemnitee to provide, or continue to provide, services to the Company, the Company wishes to provide for the
indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law;

 

WHEREAS,
it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses
on behalf of, Indemnitee to the fullest extent permitted by applicable law so that Indemnitee will serve or continue to serve
the Company free from undue concern that he or she will not be so indemnified.

 

NOW,
THEREFORE, in consideration of the foregoing and Indemnitee’s agreement to provide, or continue to provide, services to
the Company, the Company and Indemnitee hereby agree as set forth below.

 

1.
Certain Definitions.

 

(a)
“Board” shall mean the Board of Directors of the Company.

 

(b)
“Change in Control” shall mean (i) any “person” (as such term is used in Sections 13(d)
and 14(d) of the Exchange Act), other than a subsidiary of Interpace or a trustee or other fiduciary holding securities under
an employee benefit plan of Interpace or a subsidiary of Interpace, is or becomes the “Beneficial Owner” (as defined
in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of Interpace representing 50% or more of the total
voting power represented by Interpace’s then outstanding capital stock or (ii) during any period of two consecutive years,
individuals who at the beginning of such period constitute the Board and any new director whose election by the Board or nomination
for election by Interpace’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still
in office who either were directors at the beginning of the period or whose election or nomination for election was previously
so approved, cease for any reason to constitute a majority of the Board, or (iii) the stockholders of Interpace approve a merger
or consolidation of Interpace with any other corporation, other than a merger or consolidation that would result in the outstanding
capital stock of Interpace outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by
being converted into capital stock of the surviving entity) more than 50% of the total voting power represented by the capital
stock of Interpace or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of
Interpace approve a plan of complete liquidation of Interpace.

 

    	 	 	 

     

    

 

(c)
“Claim” shall mean any threatened, pending or completed action, suit, proceeding or alternative dispute
resolution mechanism, or any hearing, inquiry or investigation that Indemnitee in good faith believes might lead to the institution
of any such action, suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal, administrative, whether
formal or informal, investigative or other.

 

(d)
References to the “Company” shall include, in addition to Interpace, any constituent corporation (including
any constituent of a constituent) absorbed in a consolidation or merger to which Interpace (or any of its wholly owned subsidiaries)
is a party which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers,
employees, agents or fiduciaries, so that if Indemnitee is or was a director, officer, employee, agent or fiduciary of such constituent
corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee, agent or fiduciary
of another corporation, partnership, joint venture, employee benefit plan, trust or other enterprise, Indemnitee shall stand in
the same position under the provisions of this Agreement with respect to the resulting or surviving corporation as Indemnitee
would have with respect to such constituent corporation if its separate existence had continued.

 

(e)
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

 

(f)
“Expenses” shall mean any and all expenses (including attorneys’ fees and all other costs, expenses
and obligations) incurred in connection with investigating, defending, being a witness in or participating in (including on appeal),
or preparing to defend, to be a witness in or to participate in, any action, suit, proceeding, alternative dispute resolution
mechanism, hearing, inquiry or investigation, whether formal or informal.

 

(g)
“Expense Advance” shall mean an advance payment of Expenses to Indemnitee pursuant to Section 3(a)
hereof.

 

(h)
“Indemnifiable Event” shall mean any event or occurrence related to the fact that Indemnitee is or was
a director, officer, employee, agent or fiduciary of the Company, or any subsidiary of the Company, or is or was serving at the
request of the Company as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture,
trust or other enterprise, or by reason of any action or inaction on the part of Indemnitee while serving in such capacity.

 

(i)
“Independent Directors” shall mean those members of the Board consisting of directors who are not parties
to the Claim.

 

(j)
“Independent Legal Counsel” shall mean an attorney or firm of attorneys, who shall not have otherwise
performed services for the Company or Indemnitee within the last three years (other than with respect to matters concerning the
rights of Indemnitee under this Agreement, or of other indemnitees under similar indemnity agreements).

 

(k)
“Other Liabilities” shall mean judgments, fines, penalties and amounts paid in settlement (if such settlement
is approved in advance by the Company, which approval shall not be unreasonably withheld) of any Claim regarding any Indemnifiable
Event and any federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of
any payments under this Agreement.

 

    	 	2	 

     

    

 

(l)
References to “other enterprises” shall include employee benefit plans; references to “fines”
shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to “serving
at the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary of
the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect
to an employee benefit plan, its participants or its beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall
be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

(m)
“Reviewing Party” shall mean an election made from among the following: (i) those members of the Board
who are Independent Directors even though less than a quorum; (ii) a committee of Independent Directors designated by a majority
of the Independent Directors, even though less than a quorum; or (iii) Independent Legal Counsel selected by the Indemnitee and
approved by the Company (which approval shall not be unreasonably withheld), provided that notwithstanding the foregoing, following
any Change in Control subsequent to the date of this Agreement, the Reviewing Party shall be Independent Legal Counsel selected
in the manner provided herein.

 

2.
Indemnification.

 

(a)
Indemnification of Expenses and Other Liabilities. The Company shall indemnify Indemnitee to the fullest extent permitted
by law if Indemnitee was or is or becomes a party to or witness or other participant in, or is threatened to be made a party to
or witness or other participant in, any Claim by reason of (or arising in part out of) any Indemnifiable Event against Expenses
and Other Liabilities, including all interest, assessments and other charges paid or payable in connection with or in respect
of such Expenses. Indemnitee hereby agrees to repay to the Company all amounts advanced to Indemnitee hereunder if it is ultimately
determined that Indemnitee is not entitled to indemnification hereunder. Other than in respect of Expense Advances paid in accordance
with Section 3(a) hereof, such payment of Expenses shall be made by the Company as soon as practicable but in any event
no later than five (5) business days after written demand by Indemnitee therefor is presented to the Company.

 

(b)
Determination of Right to Indemnification. Unless otherwise provided in Section 11 hereof, the Company shall indemnify
Indemnitee pursuant to Section 2(a) hereof if Indemnitee has not failed to meet the applicable standard of conduct for
indemnification. With respect to all matters arising concerning whether or not the Indemnitee has met the applicable standard
of conduct, the Indemnitee shall be entitled to select the Reviewing Party. The Reviewing Party shall determine whether and to
what extent Indemnitee would be permitted to be indemnified under applicable law and the Company and Indemnitee agree to abide
by such determination, which, if made by Independent Legal Counsel shall be made in a written opinion.

 

(c)
Mandatory Payment of Expenses. Notwithstanding any other provision of this Agreement other than Section 11 hereof,
to the extent that Indemnitee has been successful on the merits or otherwise, including, without limitation, the dismissal of
an action without prejudice, in defense of any Claim regarding any Indemnifiable Event, Indemnitee shall be indemnified against
all Expenses incurred by Indemnitee in connection therewith.

 

    	 	3	 

     

    

 

3.
Expenses; Indemnification Procedure.

 

(a)
Advancement of Expenses. The Company shall advance all Expenses incurred by Indemnitee. The advances to be made hereunder
shall be paid by the Company to Indemnitee as soon as practicable but in any event no later than 30 days after written demand
by Indemnitee therefor to the Company. Indemnitee hereby agrees to repay to the Company all amounts advanced to Indemnitee hereunder
if it is ultimately determined that Indemnitee is not entitled to indemnification hereunder. The Company’s obligation to
advance Expenses shall terminate with respect to any Claim as to which the Indemnitee shall have entered a plea of guilty or nolo
contendere, or an equivalent plea acknowledging guilt.

 

(b)
Notice/Cooperation by Indemnitee. Indemnitee shall, as a condition precedent to Indemnitee’s right to be indemnified
under this Agreement, give the Company notice in writing as soon as practicable of any Claim made against Indemnitee for which
indemnification will or could be sought under this Agreement; provided however that the failure to so provide notice to the Company
shall not relieve the Company from any liability that it may have to Indemnitee hereunder unless the Company’s ability to
participate in the defense of such claim was materially and adversely affected by such failure. Notice to the Company shall be
directed to the Chief Executive Officer of the Company at the address set forth in Section 15 hereof (or such other address
as the Company shall designate in writing to Indemnitee). In addition, Indemnitee shall give the Company such information and
cooperation as it may reasonably require and as shall be within Indemnitee’s power. The Company shall provide Indemnitee
with such information and cooperation as Indemnitee may reasonably require, to the extent that doing so is consistent with the
Company’s obligation to cooperate with regulatory or law enforcement agencies.

 

(c)
No Presumptions; Burden of Proof. For purposes of this Agreement, the termination of any Claim by judgment, order, settlement
(whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create
a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has
determined that indemnification is not permitted by applicable law.

 

(d)
Notice to Insurers. If, at the time of the receipt by the Company of a notice of a Claim pursuant to Section 3(b)
hereof, the Company has liability insurance in effect which may cover such Claim, the Company shall give prompt notice of the
commencement of such Claim to the insurers in accordance with the procedures set forth in the respective policies. The Company
shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts
payable as a result of such Claim in accordance with the terms of such policies. The Company shall keep Indemnitee reasonably
informed as to the status of all relevant insurance matters.

 

(e)
Assumption of Defense; Selection of Counsel. In the event the Company shall be obligated hereunder to pay the Expenses
of any Claim, the Company, if appropriate, shall be entitled to assume the defense of such Claim with counsel approved by Indemnitee
(not to be unreasonably withheld) upon the delivery to Indemnitee of written notice of the Company’s election so to do.
After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company
will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect
to the same Claim; provided that, (i) Indemnitee shall have the right to employ Indemnitee’s separate counsel in any such
Claim at Indemnitee’s own expense and (ii) if (A) the employment of separate counsel by Indemnitee has been previously authorized
by the Company, (B) Indemnitee shall have reasonably concluded, with advice of counsel, that there may be a conflict of interest
between the Company and Indemnitee in the conduct of any such defense, (C) after a Change in Control, the employment of separate
counsel by Indemnitee has been approved by Independent Legal Counsel, or (D) the Company shall not continue to retain counsel
to defend such Claim, then the fees and expenses of Indemnitee’s separate counsel shall be considered an Expense.

 

    	 	4	 

     

    

 

4.
Additional Indemnification Rights; Nonexclusivity.

 

(a)
Scope. The Company hereby agrees to indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that
such indemnification is not specifically authorized by the other provisions of this Agreement, the Company’s Certificate
of Incorporation as now in effect and as may be amended and/or restated from time to time (the “Certificate of Incorporation”),
the Company’s Bylaws as now in effect and as may be amended and/or restated from time to time (the “Bylaws”)
or by statute. In the event of any change after the date of this Agreement in any applicable law, statute or rule which expands
the right of a Delaware corporation to indemnify a member of its board of directors or an officer, employee, agent or fiduciary,
it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits afforded by such change.
In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware corporation to indemnify
a member of its board of directors or an officer, employee, agent or fiduciary, such change, to the extent not otherwise required
by such law, statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties’ rights
and obligations hereunder except as set forth in Section 11(a) hereof.

 

(b)
Nonexclusivity. The indemnification provided by this Agreement shall be in addition to any rights to which Indemnitee may
be entitled under the Certificate of Incorporation, the Bylaws, any other agreement, any vote of stockholders or disinterested
directors, the General Corporation Law of the State of Delaware, or otherwise (each, an “Other Indemnity Provision”).
The indemnification provided under this Agreement shall continue as to Indemnitee for any action taken or not taken while serving
in an indemnified capacity even though Indemnitee may have ceased to serve in such capacity.

 

(c)
Primary Indemnification. The Company hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement
of expenses or liability insurance provided by a third party investor and/or certain of its affiliates (collectively, the “Other
Indemnitors”). The Company hereby agrees that it is the indemnitor of first resort of Indemnitee with respect to
matters for which indemnification is provided under this Agreement and that the Company will be obligated to make all payments
due to or for the benefit of Indemnitee under this Agreement without regard to any rights that Indemnitee may have against the
Other Indemnitors. The Company hereby waives any equitable rights to contribution or indemnification from the Other Indemnitors
in respect of any amounts paid to Indemnitee hereunder or under any Other Indemnity Provision. The Company further agrees that
no payment of Expenses or Other Liabilities by any Other Indemnitor to or for the benefit of Indemnitee shall affect the obligations
of the Company hereunder or under any Other Indemnity Provision, and that the Company shall be obligated to repay the Other Indemnitors
for all amounts so paid or reimbursed to the extent that the Company has an obligation to indemnify Indemnitee for such Expenses
or Other Liabilities hereunder or under any Other Indemnity Provision. The Company and Indemnitee agree that the Other Indemnitors
are express third party beneficiaries of this Section 4(c).

 

    	 	5	 

     

    

 

5.
Contribution.

 

(a)
Whether or not the indemnification provided in Section 2 hereof is available, in respect of any threatened, pending or
completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action,
suit or proceeding), the Company shall, unless indemnification would not be available as a result of Section 11 hereof,
pay, in the first instance, the entire amount of any judgment or settlement of such action, suit or proceeding without requiring
Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have
against Indemnitee. The Company shall not enter into any settlement of any action, suit or proceeding in which the Company is
jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding) unless such settlement provides for
a full and final release of all claims asserted against Indemnitee.

 

(b)
Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee
shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action,
suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding),
the Company shall contribute to the amount of expenses (including attorneys’ fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received
by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee
(or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction
from which such action, suit or proceeding arose; provided, however, that the proportion determined on the basis of relative benefit
may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all
officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined
in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the events that resulted
in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which the Law may require
to be considered. The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee,
who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee,
on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by
intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which
their conduct is active or passive.

 

(c)
The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought
by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.

 

    	 	6	 

     

    

 

(d)
To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to
Indemnitee for any reason whatsoever other than the reasons set forth in Section 11 hereof, the Company, in lieu of indemnifying
Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts
paid or to be paid in settlement and/or for Expenses and Other Liabilities, in connection with any claim relating to an indemnifiable
event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such proceeding
in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s)
giving cause to such proceeding; and/or (ii) the relative fault of the Company (and its directors (other than Indemnitee) officers,
employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

6.
Settlement. The Company acknowledges that a settlement or other disposition short of final judgment may be successful if
it permits a party to avoid expense, delay, distraction, disruption and uncertainty. In the event that any action, claim or proceeding
to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without
limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be
presumed that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding. Anyone seeking to
overcome this presumption shall have the burden of proof.

 

7.
No Duplication of Payments. The Company shall not be liable under this Agreement to make any payment in connection with
any Claim made against Indemnitee to the extent Indemnitee has otherwise actually received payment (under any insurance policy,
provision of the Certificate of Incorporation, Bylaws or otherwise) of the amounts otherwise indemnifiable hereunder.

 

8.
Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company
for some or a portion of Expenses or Other Liabilities incurred in connection with any Claim, but not, however, for all of the
total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such Expenses and Other Liabilities
to which Indemnitee is entitled.

 

9.
No Imputation. The knowledge or actions, or failure to act, of any director, officer, agent or employee of the Company
or the Company itself shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

10.
Liability Insurance. For the duration of Indemnitee’s service as a director or officer or other agent of the Company,
and thereafter for so long as Indemnitee shall be subject to any pending or possible Claim by reason of any Indemnifiable Event,
the Company shall use commercially reasonable efforts (taking into account the scope and amount of coverage available relative
to the cost thereof) to cause to be maintained in effect policies of liability insurance providing coverage for directors and
officers of the Company that are at least substantially comparable in scope and amount to that provided by the Company’s
current policies of directors’ and officers’ liability insurance. To the extent the Company maintains liability insurance
applicable to directors, officers, employees, agents or fiduciaries, Indemnitee shall be covered by such policies in such a manner
as to provide Indemnitee the same rights and benefits as are provided to the most favorably insured of the Company’s directors,
if Indemnitee is a director; or of the Company’s officers, if Indemnitee is not a director of the Company but is an officer;
or of the Company’s key employees, agents or fiduciaries, if Indemnitee is not an officer or director but is a key employee,
agent or fiduciary.

 

    	 	7	 

     

    

 

11.
Exceptions. Notwithstanding any other provision of this Agreement, the Company shall not be obligated pursuant to the terms
of this Agreement:

 

(a)
Excluded Action or Omissions. To indemnify Indemnitee for acts, omissions or transactions if a final decision by a court
having jurisdiction in the matter shall determine that such indemnification is prohibited by applicable law.

 

(b)
Claims Initiated by Indemnitee. To indemnify Expenses or Other Liabilities or advance Expenses to Indemnitee with respect
to Claims initiated or brought voluntarily by Indemnitee and not by way of defense, except (i) with respect to actions or proceedings
brought to establish or enforce a right to indemnification under the Certificate of Incorporation, (ii) in specific cases if the
Board has approved the initiation or bringing of such Claim, or (iii) as otherwise required by applicable law, regardless of whether
Indemnitee ultimately is determined to be entitled to such indemnification, advance Expense payment or insurance recovery, as
the case may be.

 

(c)
Lack of Good Faith. To indemnify Indemnitee for any Expenses or Other Liabilities incurred by the Indemnitee with respect
to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if a court of competent jurisdiction determines
that each of the material assertions made by the Indemnitee in such proceeding was not made in good faith or was frivolous.

 

(d)
Claims Under Section 16(b). To indemnify Indemnitee for the payment of profits arising from the purchase and sale by Indemnitee
of securities in violation of Section 16(b) of the Exchange Act, or any similar successor statute; provided that the Company shall
advance Expenses in connection with Indemnitee’s defense of a claim under Section 16(b), which advances shall be repaid
to the Company if it is ultimately determined that Indemnitee is not entitled to indemnification of such Expenses.

 

(e)
Reimbursement. To indemnify Indemnitee for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based
or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required
in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company
pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment
to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley
Act), or any reimbursements or clawbacks of compensation under Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection
Act.

 

12.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall constitute an original.

 

    	 	8	 

     

    

 

13.
Binding Effect; Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of and be enforceable
by the parties hereto and their respective successors, assigns (including any direct or indirect successor by purchase, merger,
consolidation or otherwise to all or substantially all of the business or assets of the Company), spouses, heirs and personal
and legal representatives. The Company shall require and cause any successor (whether direct or indirect, and whether by purchase,
merger, consolidation or otherwise) to all, substantially all, or a substantial part, of the business or assets of the Company,
by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.
This Agreement shall continue in effect regardless of whether Indemnitee continues to serve as a director, officer, employee,
agent or fiduciary (as applicable) of the Company or of any other enterprise at the Company’s request.

 

14.
Attorneys’ Fees. In the event that any action is instituted by Indemnitee under this Agreement or under any liability
insurance policies maintained by the Company to enforce or interpret any of the terms hereof or thereof, Indemnitee shall be entitled
to be paid all Expenses incurred by Indemnitee with respect to such action, regardless of whether Indemnitee is ultimately successful
in such action, and shall be entitled to the advancement of Expenses with respect to such action, unless as a part of such action
a court of competent jurisdiction over such action determines that each of the material assertions made by Indemnitee as a basis
for such action was not made in good faith or was frivolous. In the event of an action instituted by or in the name of the Company
under this Agreement to enforce or interpret any of the terms of this Agreement, Indemnitee shall be entitled to be paid all Expenses
incurred by Indemnitee in defense of such action (including costs and Expenses incurred with respect to Indemnitee’s counterclaims
and cross-claims made in such action), and shall be entitled to the advancement of Expenses with respect to such action.

 

15.
Notice. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed
duly given, if delivered, mailed or sent, as applicable, to the applicable address set forth below, (i) if delivered by hand and
signed for by the party addressed, on the date of such delivery, (ii) if mailed by domestic certified or registered mail with
postage prepaid, on the third business day after the date postmarked or (iii) if sent by a reputable nationwide overnight courier
service for next business day delivery, on the next business day after being sent:

 

(a)
if to Indemnitee, to the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall
provide to the Company in accordance with this Section 15; and

 

(b)
if to the Company, to:

 

Interpace
Biosciences, Inc.

Morris
Corporate Center 1, Building C

300
Interpace Parkway

Parsippany,
NJ 07054

 

or
such other address as the Company shall provide to Indemnitee in accordance with this Section 15.

 

16.
Consent to Jurisdiction. The Company and Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of
the State of Delaware for all purposes in connection with any action or proceeding which arises out of or relates to this Agreement
and agree that any action instituted under this Agreement shall be commenced, prosecuted and continued only in the Court of Chancery
of the State of Delaware in and for New Castle County, which shall be the exclusive and only proper forum for adjudicating such
a claim.

 

    	 	9	 

     

    

 

17.
Severability. The provisions of this Agreement shall be severable in the event that any of the provisions hereof (including
any provision within a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void
or otherwise unenforceable, and the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore,
to the fullest extent possible, the provisions of this Agreement (including, without limitations, each portion of this Agreement
containing any provision held to be invalid, void or otherwise unenforceable, that is not itself invalid, void or unenforceable)
shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

18.
Choice of Law. This Agreement shall be governed by and its provisions construed and enforced in accordance with the laws
of the State of Delaware as applied to contracts between Delaware residents entered into and to be performed entirely within the
State of Delaware.

 

19.
Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment
to all of the rights of recovery of Indemnitee (other than against the Other Indemnitors), who shall execute all documents required
and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce
such rights.

 

20.
Amendment and Termination. Due to the uncertain application of any statutes of limitations that may govern any Claim, this
Agreement shall be of indefinite duration. No amendment, modification, termination or cancellation of this Agreement shall be
effective unless it is in writing signed by both the parties hereto. No waiver of any of the provisions of this Agreement shall
be deemed to be or shall constitute a waiver of any other provisions hereof (whether or not similar), nor shall such waiver constitute
a continuing waiver.

 

21.
Integration and Entire Agreement. This Agreement sets forth the entire understanding between the parties hereto and supersedes
and merges all previous written and oral negotiations, commitments, understandings and agreements relating to the subject matter
hereof between the parties hereto. If the Company and Indemnitee have previously entered into an indemnification agreement providing
for indemnification of Indemnitee by the Company, the parties’ entry into this Indemnification Agreement shall be deemed
to amend and restate such Indemnification Agreement to read in its entirety as, and to be superseded by, this Indemnification
Agreement.

 

22.
No Construction as Employment Agreement. Nothing contained in this Agreement shall be construed as giving Indemnitee any
right to be retained in the employ of the Company or any of its subsidiaries or affiliated entities.

 

[Signature
Page Follows]

 

    	 	10	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement as of the date first above written.

 

	INTERPACE
    BIOSCIENCES, INC.	 
	 	 	 
	By:	 	 
	Name:	Jack
    E. Stover	 
	Title:	Chief
    Executive Officer	 

 

	 	AGREED
    TO AND ACCEPTED:
	 	 
	 	INDEMNITEE:
	 	[      ]
	 	 
	 	 
	 	(signature)
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	(address)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]